KMG Chemicals 10-K 30 Oct 13 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jul. 31, 2013	Oct. 28, 2013	Jan. 31, 2013
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Jul-13
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Trading Symbol	KMG
Entity Registrant Name	KMG CHEMICALS INC
Entity Central Index Key	1028215
Current Fiscal Year End Date	-24
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		11,610,449
Entity Public Float			$162,600,000

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jul. 31, 2013	Jul. 31, 2012
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$13,949	$1,633
Accounts receivable
Trade, net of allowances of $224 at July 31, 2013 and $16 at July 31, 2012	41,935	28,933
Other	4,210	960
Inventories, net	53,387	40,661
Current deferred tax assets	1,400	1,417
Prepaid expenses and other	3,955	2,057
Total current assets	118,836	75,661
Property, plant and equipment, net	96,688	68,026
Deferred tax assets	1,069	1,129
Goodwill	10,929	3,778
Intangible assets, net	29,261	14,980
Restricted cash	1,000	1,000
Other assets, net	4,232	3,116
Total assets	262,015	167,690
Current liabilities
Accounts payable	35,492	21,855
Accrued liabilities	8,362	4,595
Employee incentive accrual	1,989	2,227
Total current liabilities	45,843	28,677
Long-term debt, net of current maturities	85,000	24,000
Deferred tax liabilities	11,462	7,046
Other long-term liabilities	2,470	1,200
Total liabilities	144,775	60,923
Commitments and contingencies
Stockholders' equity
Preferred stock, $.01 par value, 10,000,000 shares authorized, none issued
Common stock, $.01 par value, 40,000,000 shares authorized, 11,522,321 shares issued and outstanding at July 31, 2013 and 11,405,808 shares issued and outstanding at July 31, 2012	115	114
Additional paid-in capital	26,689	26,022
Accumulated other comprehensive loss	-2,504	-4,339
Retained earnings	92,940	84,970
Total stockholders' equity	117,240	106,767
Total liabilities and stockholders' equity	$262,015	$167,690

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jul. 31, 2013	Jul. 31, 2012
In Thousands, except Share data, unless otherwise specified
Allowances for accounts receivables	$224	$16
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	11,522,321	11,405,808
Common stock, shares outstanding	11,522,321	11,405,808

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Net sales	$263,311	$272,700	$255,596
Cost of sales	186,841	195,635	187,536
Gross profit	76,470	77,065	68,060
Distribution expenses	30,312	26,770	28,821
Selling, general and administrative expenses	28,978	24,858	22,217
Operating income	17,180	25,437	17,022
Other income/(expense)
Interest expense, net	-1,771	-2,099	-2,335
Other, net	-208	-269	-208
Total other expense, net	-1,979	-2,368	-2,543
Income from continuing operations before income taxes	15,201	23,069	14,479
Provision for income taxes	-5,715	-8,754	-5,061
Income from continuing operations	9,486	14,315	9,418
Discontinued operations
Income/(loss) from discontinued operations, before income taxes	-203	-711	514
Income tax benefit/(expense)	65	221	-203
Income/(loss) from discontinued operations	-138	-490	311
Net income	$9,348	$13,825	$9,729
Basic
Income from continuing operations	$0.82	$1.26	$0.83
Income/(loss) from discontinued operations	($0.01)	($0.04)	$0.03
Net income	$0.81	$1.22	$0.86
Diluted
Income from continuing operations	$0.82	$1.24	$0.82
Income/(loss) from discontinued operations	($0.01)	($0.04)	$0.03
Net income	$0.81	$1.20	$0.85
Weighted average shares outstanding
Basic	11,487	11,363	11,309
Diluted	11,578	11,528	11,489

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Net income	$9,348	$13,825	$9,729
Other comprehensive income/(loss)
Foreign currency translation gain/(loss)	1,835	-3,106	2,102
Total other comprehensive income/(loss)	1,835	-3,106	2,102
Total comprehensive income	$11,183	$10,719	$11,831

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Share data in Thousands
Beginning Balance at Jul. 31, 2010	$84,778,000	$112,000	$24,319,000	($3,335,000)	$63,682,000
Beginning Balance (in shares) at Jul. 31, 2010		11,229
Cash dividends	-1,017,000				-1,017,000
Stock options/warrants exercised, Shares		50
Stock options/warrants exercised, Value	200,000		200,000
Restricted stock issued, Shares		40
Restricted stock issued, Value		1,000	-1,000
Stock-based compensation expense	542,000		542,000
Tax benefit from stock-based awards	196,000		196,000
Net income	9,729,000				9,729,000
Gain (Loss) on foreign currency translation	2,102,000			2,102,000
Ending Balance at Jul. 31, 2011	96,530,000	113,000	25,256,000	-1,233,000	72,394,000
Ending Balance (in shares) at Jul. 31, 2011		11,319
Cash dividends	-1,249,000				-1,249,000
Stock options/warrants exercised, Shares		37
Stock options/warrants exercised, Value	55,000		55,000
Restricted stock issued, Shares		50
Restricted stock issued, Value		1,000	-1,000
Stock-based compensation expense	714,000		714,000
Tax benefit from stock-based awards	41,000		41,000
Other	-43,000		-43,000
Net income	13,825,000				13,825,000
Gain (Loss) on foreign currency translation	-3,106,000			-3,106,000
Ending Balance at Jul. 31, 2012	106,767,000	114,000	26,022,000	-4,339,000	84,970,000
Ending Balance (in shares) at Jul. 31, 2012		11,406
Cash dividends	-1,378,000				-1,378,000
Stock options/warrants exercised, Shares		70
Stock options/warrants exercised, Value	70,000		70,000
Restricted stock issued, Shares		46
Restricted stock issued, Value		1,000	-1,000
Stock-based compensation expense	446,000		446,000
Tax benefit from stock-based awards	529,000		529,000
Other	-377,000		-377,000
Net income	9,348,000				9,348,000
Gain (Loss) on foreign currency translation	1,835,000			1,835,000
Ending Balance at Jul. 31, 2013	$117,240,000	$115,000	$26,689,000	($2,504,000)	$92,940,000
Ending Balance (in shares) at Jul. 31, 2013		11,522

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Cash dividend per share	$0.12	$0.11	$0.09

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Cash flows from operating activities
Net income	$9,348	$13,825	$9,729
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	8,295	7,018	7,354
Amortization of loan costs included in interest expense	41	124	109
Stock-based compensation expense	446	714	542
Bad debt expense	208		154
Allowance for excess and obsolete inventory	-355	371	-94
(Gain) loss on sale of animal health business	57	-90
Loss on disposal of property	59	99	112
Deferred income tax expense	1,247	929	2,083
Tax benefit from stock-based awards	-529	-41	-196
Changes in operating assets and liabilities, net of effects of acquisition
Accounts receivable - trade	1,813	6,810	-5,909
Accounts receivable - other	-2,593	2,186	-1,370
Inventories	-1,018	-5,545	-2,230
Other current and non-current assets	-654	-223	-1,128
Accounts payable	5,301	-2,801	3,792
Accrued liabilities and other	-1,394	1,873	-235
Net cash provided by operating activities	20,272	25,249	12,713
Cash flows from investing activities
Additions to property, plant and equipment	-5,505	-5,193	-8,268
Acquisition of Ultra Pure Chemicals, net of cash acquired	-62,608
Proceeds from sale of animal health business		10,203
Proceeds from sale of property		33	60
Change in restricted cash		-1,000	201
Net cash provided by/(used in) investing activities	-68,113	4,043	-8,007
Cash flows from financing activities
Deferred financing costs	-229
Net borrowings/(payments) under revolving loan facility	61,000	-13,946	-2,054
Principal payments on borrowings on term loan		-11,333	-8,000
Proceeds from exercise of stock options and warrants	70	64	200
Tax benefit from stock-based awards	529	41	196
Book overdraft		-2,852	2,852
Payment of dividends	-1,378	-1,249	-1,017
Net cash provided by/(used in) financing activities	59,992	-29,275	-7,823
Effect of exchange rate changes on cash	165	-210	215
Net increase (decrease) in cash and cash equivalents	12,316	-193	-2,902
Cash and cash equivalents at the beginning of year	1,633	1,826	4,728
Cash and cash equivalents at end of year	13,949	1,633	1,826
Supplemental disclosures of cash flow information
Cash paid for interest	1,709	1,896	2,294
Cash paid for income taxes	5,854	5,009	4,387
Supplemental disclosure of non-cash investing activities
Purchase of property, plant and equipment through accounts payable	$649

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2013
Summary Of Significant Accounting Policies	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	General — KMG Chemicals, Inc. (the “Company”) is involved principally in the manufacture, formulation and distribution of specialty chemicals in carefully focused markets through its two wholly-owned subsidiaries, KMG Electronic Chemicals, Inc. (“KMG EC”) and KMG-Bernuth, Inc. (“KMG Bernuth”).
	In its electronic chemicals business, the Company sells high purity wet process chemicals to the semiconductor industry, and in the wood treating chemicals business the Company sells two industrial wood treating chemicals, pentachlorophenol (“penta”) and creosote. The Company operates its electronic chemicals business through KMG EC in North America and through KMG Italia, S.r.l. (“KMG Italia”) and KMG Electronic Chemicals Holdings S.a.r.l (“KMG Lux”) (and its subsidiaries) in Europe and elsewhere. That business has facilities in the United States, the United Kingdom, France, Italy and Singapore. In the wood treating business the Company manufactures penta at its plant in Matamoros, Mexico through KMG de Mexico (“KMEX”), a Mexican corporation which is a wholly-owned subsidiary of KMG Bernuth. The Company sells its wood treating chemicals in the United States, Mexico and Canada. The electronic chemicals and wood treating businesses constitute two reportable segments that the Company considers of equal importance. See Note 13.
	Principles of Consolidation — The consolidated financial statements include the accounts of KMG Chemicals, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Reclassifications — Certain reclassifications of prior year amounts have been made to conform to current year presentation.
	Cash and Cash Equivalents — The Company considers all investments with original maturities of three months or less when purchased to be cash equivalents. The Company reduces cash balances when checks are disbursed. Due to the time delay in checks clearing the banks, the Company reports a negative balance in its cash disbursement accounts as a current liability which is reflected as book overdraft in the consolidated balance sheets. The Company did not have a negative cash balance as of July 31, 2013.
	Restricted Cash — Restricted cash includes cash balances which are legally or contractually restricted to use. The Company’s restricted cash as of July 31, 2013 and 2012 includes proceeds that were placed in escrow in connection with the sale of the animal health business. See Note 12.
	Fair Value of Financial Instruments — The carrying value of financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of the relatively short maturity of these instruments. The fair value of the Company’s debt at July 31, 2013 and 2012 approximated its carrying value since the debt obligations bear interest at a rate consistent with market rates.
	Accounts Receivable — The Company’s trade accounts receivable are primarily from wood-treating customers and from electronic chemical customers worldwide. The Company extends credit based on an evaluation of the customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is dependent on each customer’s financial condition. At July 31, 2013 there were two customers that represented approximately 12% and 14%, respectively of the Company’s accounts receivable, and at July 31, 2012 there were two customers that represented approximately 12% and 17%, respectively, of the Company’s accounts receivable.
	The Company records an allowance for doubtful accounts to reduce accounts receivable when the Company believes an account may not be collected. A provision for bad debt expense is recorded to selling, general and administrative expenses. The amount of bad debt expense recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a customer-by-customer analyses of accounts receivable balances each period and our assessment of future bad debt exposure. Historically, write offs of accounts receivable balances have been insignificant. The allowance was $224,000 and $16,000 at July 31, 2013 and 2012, respectively.
	Inventories — Inventories are valued at the lower of cost or market. For certain products, cost is generally determined using the first-in, first-out (“FIFO”) method. For certain other products the Company utilizes a weighted-average cost. The Company records inventory obsolescence as a reduction in its inventory when considered unsellable.
	Property, Plant, and Equipment — Property, plant, and equipment are stated at cost less accumulated depreciation and amortization. Major renewals and betterments are capitalized. Repairs and maintenance costs are expensed as incurred.
	Depreciation for equipment commences once placed in service, and depreciation for buildings and leasehold improvements commences once they are ready for their intended use. Depreciable life is determined through economic analysis. Depreciation for financial statement purposes is provided on the straight-line method.
	The estimated useful lives of classes of assets are as follows:
	Asset Class	Life (Years)
	Building	15 to 30
	Plant	10 to 18
	Equipment	3 to 15
	Leasehold improvements	remaining life
		of the lease
	Depreciation expense was approximately $7.7 million, $6.5 million and $6.3 million in fiscal years 2013, 2012 and 2011, respectively.
	Intangible Assets — Identifiable intangible assets with a defined life are amortized using a straight-line or accelerated method over the useful lives of the assets. Identifiable intangible assets of an indefinite life are not amortized. These assets are required to be tested for impairment at least annually. If this review indicates that impairment has occurred, the Company’s carrying value of intangibles will be adjusted to fair value. Based on an assessment of qualitative factors, in accordance with GAAP, it was determined that there were no events or circumstances that would lead the Company to a determination that is more likely than not that the fair value of the applicable assets was less than its carrying value as of July 31, 2013 and 2012. The Company concluded that as a result its indefinite lived intangible assets were not impaired as of July 31, 2013 and 2012. It is the Company’s policy to expense costs as incurred in connection with the renewal or extension of its intangible assets.
	Goodwill — The Company has goodwill of $3.8 million and $7.1 million, respectively, associated with its wood treating and electronic chemicals segments. The carrying value of the Company’s goodwill is reviewed at least annually, and if this review indicates that it will not be recoverable the Company’s carrying value of goodwill will be adjusted to fair value. Based on an assessment of qualitative factors it was determined that there were no events or circumstances that would lead the Company to a determination that is more likely than not that the fair value of the applicable reporting unit was less than its carrying value as of July 31, 2013 and 2012. Accordingly, the Company determined that as of July 31, 2013 and 2012, goodwill was not impaired. As a result, there was no change in the carrying value of goodwill as of July 31, 2013 and 2012, respectively, except for an increase in goodwill of $7.1 million in connection with the acquisition of the electronic chemicals business subsidiaries of OM Group, Inc. See Note 2.
	Impairment of Long-Lived Assets — Long-lived assets, including property, plant and equipment, and intangible assets with defined lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its disposition. The measurement of an impairment loss for long-lived assets, where management expects to hold and use the asset, are based on the asset’s estimated fair value. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value.
	Revenue Recognition — The Company’s chemical products are sold in the open market and revenue is recognized when risk of loss and title to the products transfers to customers. In general, risk of loss transfers upon shipment to customers. The Company also recognizes service revenue in connection with technical support services and chemicals delivery and handling at customer facilities. Revenue is recognized as those services are provided.
	Cost of Sales — Cost of sales includes inbound freight charges, purchasing and receiving costs, depreciation, inspection costs and internal transfer costs. In the case of products manufactured by the Company, direct and indirect manufacturing costs (including depreciation and amortization) and associated plant administrative expenses are included as well as laid-in cost of raw materials consumed in the manufacturing process.
	Distribution Expenses — These expenses include outbound freight, depreciation, storage and handling expenses and other miscellaneous costs (including depreciation and amortization) associated with product storage, handling and distribution.
	Selling, General and Administrative Expenses — These expenses include selling expenses, corporate headquarters’ expenses, amortization of intangible assets and environmental regulatory support expenses.
	Advertising Costs — Our policy is to expense advertising costs as they are incurred. Advertising costs were approximately $26,000, $347,000 and $608,000 in fiscal years ended July 31, 2013, 2012 and 2011, respectively. These costs were primarily related to the animal health business which is reported as discontinued operations in the consolidated statements of income. See Note 12.
	Shipping and Handling Costs — Shipping and handling costs are included in cost of sales and distribution expenses. Inbound freight charges and internal transfer costs are included in cost of sales. Product storage and handling costs and the cost of distributing products to the Company’s customers are included in distribution expenses.
	Income Taxes — The Company files a consolidated United States federal income tax return, and for financial reporting purposes, provides income taxes for the differences between the financial statement carrying amounts of assets and liabilities and their tax bases in accordance with GAAP. See Note 5.
	Earnings Per Share — Basic earnings per common share amounts are calculated using the average number of common shares outstanding during each period. Diluted earnings per share assumes the issuance of restricted stock awards and the exercise of stock options having exercise prices less than the average market price during the period of the common stock, using the treasury stock method.
	Foreign Currency Translation — The functional currency of the Company’s Mexico operations is the U.S. Dollar. As a result, monetary assets and liabilities for KMEX are re-measured to U.S. dollars at current rates at the balance sheet dates, income statement items are re-measured at the average monthly exchange rates for the dates those items were recognized, and certain assets (including plant and production equipment) are re-measured at historical exchange rates. Foreign currency transaction gains and losses are included in the statement of operations as incurred along with gains and losses from currency re-measurement. These gains and losses were nominal in fiscal years 2013, 2012 and 2011.
	The Company’s international operations in the electronic chemicals business are in Europe and Singapore, and use local currencies as the functional currency, including the GB Pound, Euro and Singapore Dollar. The translation adjustment resulting from currency translation of the local currency into the reporting currency (U.S. Dollar) is included as a separate component of stockholders’ equity. The assets and liabilities have been translated from local currencies into U.S. Dollars using exchange rates in effect at the balance sheet dates. Results of operations have been translated using the average exchange rates during the period. Foreign currency translation resulted in a translation adjustment gains of $1.8 million and $2.1 million in fiscal years 2013 and 2011, respectively, and a loss of $3.1 million in fiscal years 2012, each of which are included in accumulated other comprehensive loss in the consolidated balance sheets.
	Stock-Based Compensation — The Company’s stock-based compensation expense is based on the fair value of the award measured on the date of grant. For stock option awards, the grant date fair value is measured using a Black-Scholes option valuation model. For stock awards, the Company’s stock price on the date of the grant is used to measure grant date fair value. For awards of stock which are based on a fixed monetary value the grant date fair value is based on the monetary value. Stock-based compensation costs are recognized as an expense over the requisite service period of the award using the straight-line method.
	Recent Accounting Standards
	The Company has considered all recently issued accounting standards updates and SEC rules and interpretive releases.
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a similar Tax Loss, or a Tax Credit Carryforward Exists.” The update was issued to reduce the diversity in presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The update requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions listed in the update. The new presentation requirements are effective for interim and annual periods beginning after December 15, 2013. Since this update only affects presentation of unrecognized tax benefits in financial statements, adoption of this standard is not expected to have a material impact on the Company’s financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Jul. 31, 2013
Acquisitions	2. ACQUISITIONS
	On May 31, 2013, the Company completed its acquisition of the ultra pure chemicals (“UPC”) business subsidiaries of OM Group, Inc. (“OM Group”) located in the United States, Europe and Singapore. The aggregate purchase price consists of cash paid at closing of $63.3 million reduced by approximately $684,000 of working capital adjustments. The subsidiaries sell high purity and ultra pure, wet process chemicals to the semiconductor industry. The Company completed the acquisition by borrowing $65.0 million on the revolving loan under a revised credit facility on May 31, 2013. See Note 7 for further discussion of the Company’s revised credit facility.
	The Company accounted for the acquisition under the acquisition method of accounting in accordance with GAAP. During the year ended July 31, 2013, the Company expensed transaction and acquisition-related costs of approximately $2.1 million, which is included in selling, general and administrative expenses on the Company’s consolidated statement of income.
	The following table summarizes the acquired assets and assumed liabilities and the preliminary acquisition accounting for the fair value of the assets and liabilities recognized in the consolidated balance sheets at the acquisition date (in thousands):
	Cash	$	689
	Accounts receivable		14,698
	Inventory		11,047
	Other current assets		1,963
	Property, plant and equipment		28,939
	Intangible assets:
	Value of product qualifications		12,800
	Non-compete agreement		1,900
	Transition services		154
	Total intangible assets		14,854
	Total assets acquired	$	72,190
	Current liabilities		11,401
	Other long-term liabilities		5,326
	Total liabilities assumed		16,727
	Net assets acquired	$	55,463
	The Company recognized goodwill of $7.1 million associated with the acquisition representing the value of the assembled workforce and expected synergies from combining operations.
	The following table sets forth pro forma results for the fiscal years ended July 31, 2013 and 2012 had the acquisition occurred as of the beginning of fiscal year 2012. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations would have been had we completed the acquisition as of the dates indicated.
		(Unaudited) (in  thousands,
		except per share data)
		2013		2012
	Revenues	$	340,427	$	366,882
	Operating income		15,955		26,083
	Net income		9,123		13,056
	Earnings per share — basic	$	0.79	$	1.15
	The Company recognized $16.0 million of net sales and net income of $979,000, and integration costs of $577,000 related to the acquired business, in its consolidated statements of income for the fiscal year ended July 31, 2013.
	The supplemental pro forma information includes incremental interest expense from the Company’s revised credit facility of $1.0 million and $1.6 million for the years ended July 31, 2013 and 2012, respectively, excludes $2.1 million of acquisition-related costs incurred in fiscal year 2013, and includes incremental depreciation and amortization expense of approximately $3.1 million and $3.3 million for the years ended July 31, 2013 and 2012, respectively.

Inventories

Inventories	12 Months Ended
	Jul. 31, 2013
Inventories	3. INVENTORIES
	Inventories are summarized as follows at July 31, 2013 and 2012 (in thousands):
		2013			2012
	Raw materials and supplies	$	8,003		$	5,846
	Work in process		1,382			896
	Supplies		1,730			1,405
	Finished products		42,452			33,007
	Less reserve for inventory obsolescence		(180	)		(493	)
	Inventories, net	$	53,387		$	40,661

Property_Plant_And_Equipment

Property, Plant And Equipment	12 Months Ended
	Jul. 31, 2013
Property, Plant And Equipment	4. PROPERTY, PLANT AND EQUIPMENT
	Property, plant, and equipment and related accumulated depreciation and amortization are summarized as follows at July 31, 2013 and 2012 (in thousands):
		2013			2012
	Land	$	15,620		$	9,034
	Buildings and improvements		41,273			35,578
	Equipment		66,807			45,924
	Leasehold improvements		143			143
			123,843			90,679
	Less accumulated depreciation and amortization		(36,933	)		(28,824	)
			86,910			61,855
	Construction-in-progress		9,778			6,171
	Property, plant and equipment, net	$	96,688		$	68,026

Income_Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2013
Income Taxes	5. INCOME TAXES
	The Company is subject to United States federal, state and foreign taxes on its operations. The geographical sources of income from continuing operations before income taxes for each of the three years ended July 31 are as follows (in thousands):
		2013			2012			2011
	United States	$	12,033		$	21,789		$	13,716
	Foreign		3,168			1,280			763
	Income from continuing operations before income taxes	$	15,201		$	23,069		$	14,479
	The components of income tax expense/(benefit) from continuing operations for the years ended July 31 consisted of the following (in thousands):
		2013			2012			2011
	Current:
	Federal	$	2,833		$	5,639		$	1,746
	Foreign		1,437			686			513
	State		197			1,071			719
			4,467			7,396			2,978
	Deferred:
	Federal		1,426			1,441			2,546
	Foreign		(282	)		(104	)		(648	)
	State		104			21			185
			1,248			1,358			2,083
	Total	$	5,715		$	8,754		$	5,061
	The Company allocated income tax benefit of $65,000, and $221,000 and income tax expense of $203,000 to discontinued operations for the fiscal years ended July 31, 2013, 2012 and 2011, respectively.
	Deferred income taxes are provided on all temporary differences between financial and taxable income. The following table presents the components of the Company’s deferred tax assets and liabilities at July 31, 2013 and 2012 (in thousands):
		2013			2012
	Deferred tax assets:
	Current deferred tax assets:
	Bad debt expense	$	259		$	—
	Inventory		920			780
	Accrued liabilities		590			460
	Accrued bonus		295			710
	Other		46			27
	Total current deferred tax assets	$	2,110		$	1,977
	Non-current deferred tax assets
	Net operating loss	$	803		$	411
	Difference in amortization basis of intangibles		363			—
	Difference in depreciable basis of property		731			745
	Deferred compensation		793			690
	Other		—			5
	Total non-current deferred tax assets	$	2,690		$	1,851
	Deferred tax liabilities:
	Current deferred tax liabilities:
	Other		(148	)		—
	Prepaid assets		(562	)		(560	)
	Total current deferred tax liabilities:	$	(710	)	$	(560	)
	Non-current deferred tax liabilities:
	Difference in amortization basis of intangibles	$	(6,370	)	$	(2,440	)
	Difference in depreciable basis of property		(6,713	)		(5,328	)
	Total non-current deferred tax liabilities		(13,083	)		(7,768	)
	Net current deferred tax asset	$	1,400		$	1,417
	Net non-current deferred tax liability	$	(10,393	)	$	(5,917	)
	As of July 31, 2013, the Company has $3.8 million foreign net operating losses carryforwards which do not expire.
	The Company records provisions for uncertain tax provisions in accordance with GAAP, which prescribes the minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The statute of limitations remain open for fiscal year ended July 31, 2010 and forward for United States federal income taxes and fiscal year ended July 31, 2008 and forward for state tax jurisdictions.
	The Company’s subsidiary in Italy is currently under examination for the period ended July 31, 2009. Adjustments were proposed by the taxing authority at the end of April 2011 that would result in approximately $1.6 million (including interest and penalties) of additional liability, if all the adjustments are sustained. However, the Company does not expect all of this amount to result in cash payments, as the Company would be able to utilize available net operating losses. The Company has provided additional information and additional documentary evidence in response to the proposed adjustments, and intends to vigorously defend its tax position. The ultimate outcome of this examination is subject to uncertainty, and the Company recorded a liability for its uncertain tax position in Italy in fiscal year 2013 in the amount of $437,000, which includes penalties and interest. These uncertain tax positions primarily relate to transfer pricing.
	On January 2, 2013 the American Taxpayer Relief Act was adopted. The law included a retroactive two year extension of the research and development credit from January 1, 2012 through December 31, 2013. A retroactive income tax benefit of approximately $200,000 was recorded by the Company. In July 2013, The Finance Bill 2013 included reductions in the United Kingdom corporation tax rate to 21%, effective April 2014.
	Undistributed earnings of the Company’s Mexico subsidiary amount to approximately $5.6 million at July 31, 2013. Those earnings are considered to be permanently reinvested. For the year ended July 31, 2012, the Company implemented an annual dividend policy plan for Mexico up to its current year earnings and profits. It is the Company’s intention to continue to remain permanently invested in Mexico on its prior year cumulative undistributed earnings. Accordingly, no provision for United States income taxes has been provided with respect to these undistributed earnings. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company will be subject to both United States income taxes (subject to an adjustment for foreign tax credits) and potential withholding taxes payable to the foreign country. Determination of the amount of unrecognized deferred United States income tax liability is not practicable due to the complexities associated with its hypothetical calculation.
	The following table accounts for the differences between the actual tax provision, and the amounts obtained by applying the applicable statutory United States federal income tax rate of 35% to income from continuing operations before income taxes for each of the years ended July 31, 2013, 2012, and 2011, respectively (in thousands):
		2013			2012			2011
	Income taxes at the federal statutory rate	$	5,320		$	8,074		$	5,068
	Effect of foreign operations		(65	)		160			225
	Change in valuation allowance		—			—			(627	)
	State income taxes, net of federal income tax effect		232			717			659
	Acquisition related cost		714			—			—
	Other		(486	)		(197	)		(264	)
	Total	$	5,715		$	8,754		$	5,061

Intangible_Assets

Intangible Assets	12 Months Ended
	Jul. 31, 2013
Intangible Assets	6. INTANGIBLE ASSETS
	Intangible assets are summarized as follows (in thousands):
		Number of Years
		Weighted		July 31, 2013
		Average
		Amortization		Original		Accumulated			Carrying
		Period		Cost		Amortization			Amount
	Intangible assets subject to amortization
	(range of useful life):
	Electronic chemicals-related contracts (5-8 years)		6.5	$	2,297	$	(253	)	$	2,044
	Electronic chemicals-related trademarks and patents (10-15 years)		12		117		(57	)		60
	Electronic chemicals-value of product qualifications (5-15 years)		14.1		14,100		(1,047	)		13,053
	Total intangible assets subject to amortization		13	$	16,514	$	(1,357	)		15,157
	Intangible assets not subject to amortization:
	Creosote product registrations									5,339
	Penta product registrations									8,765
	Total intangible assets not subject to amortization									14,104
	Total intangible assets, net								$	29,261
		Number of Years
		Weighted		July 31, 2012
		Average
		Amortization		Original		Accumulated			Carrying
		Period		Cost		Amortization			Amount
	Intangible assets subject to amortization
	(range of useful life):
	Creosote supply contract (10 years)		10	$	4,000	$	(4,000	)	$	—
	Electronic chemicals-related contracts (3-8 years)		3.8		1,164		(1,053	)		111
	Electronic chemicals-related trademarks and patents (10-15 years)		12		117		(46	)		71
	Electronic chemicals—value of product qualifications (5 years)		5		1,300		(606	)		694
	Total intangible assets subject to amortization		8	$	6,581	$	(5,705	)		876
	Intangible assets not subject to amortization:
	Creosote product registrations									5,339
	Penta product registrations									8,765
	Total intangible assets not subject to amortization									14,104
	Total intangible assets, net								$	14,980
	The acquisition of the UPC subsidiaries on May 31, 2013 included $12.8 million of product qualifications and $1.9 million of non-compete agreements, amortized over 15 and seven years, respectively. Intangible assets subject to amortization are amortized over their estimated useful lives which are between five and 15 years. Total amortization expense related to intangible assets was approximately $573,000, $548,000 and $1.0 million for the fiscal years ended July 31, 2013, 2012 and 2011, respectively. The estimated amortization expense is projected to be approximately $1.7 million, $1.5 million, $1.3 million, $1.3 million and $1.2 million for fiscal years 2014 through 2018, respectively.

LongTerm_Obligations

Long-Term Obligations	12 Months Ended
	Jul. 31, 2013
Long-Term Obligations	7. LONG-TERM OBLIGATIONS
	Working Capital
	The Company has a revolving line of credit under an amended and restated credit agreement. At July 31, 2013, the Company had $65.0 million outstanding under that revolving facility and a maximum $41.6 million in additional borrowing capacity, after giving effect to a reduction of $3.4 million for unused letters of credit. The actual amount available under the revolving facility at July 31, 2013 was limited, however, to approximately $18.7 million, because of a loan covenant restriction respecting funded debt to pro-forma earnings before interest, taxes and depreciation. The Company increased the maximum borrowing capacity available under the revolving line in April 2013 in anticipation of the acquisition of the UPC business subsidiaries of OM Group. Management believes that the current credit facility, combined with cash flows from operations, will adequately provide for working capital needs for current operations for the next twelve months.
	Long Term Obligations
	The Company’s long-term debt and current maturities as of July 31, 2013 and July 31, 2012 consisted of the following (in thousands):
		July 31,			July 31,
		2013			2012
	Senior Secured Debt:
	Note Purchase Agreement, maturing on December 31, 2014, interest rate of 7.43%	$	20,000		$	20,000
	Revolving Loan Facility, maturing on April 30, 2018, variable interest rates based on LIBOR plus 1.50% and 2.0% at July 31, 2013 and 2012, respectively		65,000			4,000
	Total debt		85,000			24,000
	Current maturities of long-term debt		—			—
	Long-term debt, net of current maturities	$	85,000		$	24,000
	To finance the acquisition of the electronic chemicals business in December 2007, the Company entered into an amended and restated credit agreement and a note purchase agreement. The amended and restated credit agreement is now with Wells Fargo Bank, National Association, and with Bank of America, N.A. The note purchase agreement is now with The Prudential Insurance Company of America and Pruco Life Insurance Company.
	Initially, the amended and restated credit agreement included a revolving loan facility and a term loan facility. The Company amended these facilities several times, most recently in April 2013 and May 2013, to increase the amount that may be borrowed under the revolving loan up to $110.0 million, including an accordion feature that allows for an additional revolving loan increase of up to $25.0 million with approval from the Company’s lenders, and to extend the maturity date of the revolving loan facility to April 30, 2018, with mandatory reduction in revolving loan commitment of $10.0 million each year from September 30, 2014 to September 30, 2017 totaling $40.0 million. The Company recorded $229,000 of financing costs in connection with the amendment of revolving loan facility. The matrix for the calculation of interest payable on the revolving loan facility and the method for the calculation of the fixed charge coverage ratio were also revised.
	The revolving loan bears interest at varying rate of LIBOR plus a margin based on funded debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”), as described in the table.
	Ratio of Funded Debt to EBITDA	Margin
	Equal to or greater than 2.5 to 1.0		2.25	%
	Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0		2	%
	Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0		1.75	%
	Less than 1.5 to 1.0		1.5	%
	The Company also incurs an unused commitment fee on the unused amount of commitments under revolving loan facility of 0.35% or 0.25% based on ratio of funded debt to EBITDA. Advances under the revolving loan incurred interest at 1.69% and 2.2% as of July 31, 2013 and July 31, 2012, respectively. The amount outstanding on the revolving loan facility was $65.0 million at July 31, 2013.
	During the first quarter of fiscal year 2012, the Company repaid the outstanding balance of the term loan with borrowings on the revolving loan and in a November 2011 amendment, that aspect of the facility was deleted.
	The note purchase agreement is for $20.0 million. Advances under the note purchase agreement mature December 31, 2014, and bears interest at 7.43% per annum. Principal is payable at maturity. At July 31, 2013, $20.0 million was outstanding under the note purchase agreement.
	Loans under the amended and restated credit facility and the note purchase agreement are secured by the Company’s assets, including stock in subsidiaries, inventory, accounts receivable, equipment, intangible assets, and real property. The credit facility and the note purchase agreement have restrictive covenants, including that the Company must maintain a fixed charge coverage ratio of 1.5 to 1.0, a ratio of funded debt to EBITDA (as adjusted for extraordinary items, with lender consent) of 3.0 to 1.0 and a current ratio of at least 1.5 to 1.0.
	Principal payments due under long-term debt agreements for the fiscal years ended July 31 are as follows (in thousands):
		Total			2014		2015		2016		2017		2018		Thereafter
	Long-term debt	$	85,000		$	—	$	20,000	$	—	$	—	$	65,000	$	—

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Jul. 31, 2013
Commitments And Contingencies	8. COMMITMENTS AND CONTINGENCIES
	Contractual Obligations — The Company has non-cancelable operating leases for its office and warehouse facilities and certain transportation equipment and purchase obligations. Our obligations to make future payments under certain contractual obligations as of July 31, 2013 are summarized in the following table (in thousands):
			Total		2014		2015		2016		2017		2018		Thereafter
	Operating leases		$	11,942	$	3,748	$	1,775	$	1,493	$	1,119	$	752	$	3,055
	Purchase obligations (1)			189,508		70,283		48,322		40,751		28,037		2,115		—
	Total		$	201,450	$	74,031	$	50,097	$	42,244	$	29,156	$	2,867	$	3,055
	-1	Consists primarily of raw materials purchase contracts. These are typically not fixed price arrangements. The prices are based on the prevailing market prices.
	Rent expense relating to the operating leases was approximately $2.7 million, $2.3 million and $2.0 million in fiscal years 2013, 2012 and 2011, respectively.
	Environmental — The Company’s operations are subject to extensive federal, state and local laws, regulations and ordinances in the United States and abroad relating to the generation, storage, handling, emission, transportation and discharge of certain materials, substances and waste into the environment, and various other health and safety matters. Governmental authorities have the power to enforce compliance with their regulations, and violators may be subject to fines, injunctions or both. The Company must devote substantial financial resources to ensure compliance, and it believes that it is in substantial compliance with all the applicable laws and regulations.
	Certain licenses, permits and product registrations are required for the Company’s products and operations in the United States, Mexico and other countries in which it does business. The licenses, permits and product registrations are subject to revocation, modification and renewal by governmental authorities. In the United States in particular, producers and distributors of chemicals such as penta and creosote are subject to registration and notification requirements under federal law (including under the Federal Insecticide Fungicide and Rodenticide Act (“FIFRA”), and comparable state law) in order to sell those products in the United States. Compliance with these requirements has had, and in the future will continue to have, a material effect on our business, financial condition and results of operations.
	The Company incurred expenses in connection with FIFRA research and testing programs of approximately $522,000, $802,000, and $760,000 in fiscal year 2013, 2012 and 2011, respectively. These costs are included in selling, general, and administrative expenses.
	Litigation and Other Contingencies — The Company is subject to contingencies, including litigation relating to environmental laws and regulations, commercial disputes and other matters. Certain of these contingencies are discussed below. The ultimate resolution of these contingencies is subject to significant uncertainty, and should the Company fail to prevail in any of them or should several of them be resolved against the Company in the same reporting period, these matters could, individually or in the aggregate, be material to the consolidated financial statements. The ultimate outcome of these matters, however, cannot be determined at this time, nor can the amount of any potential loss be reasonably estimated, and as a result except where indicated no amounts have been recorded in the Company’s consolidated financial statements.
	The Company records legal costs associated with loss contingencies as expenses in the period in which they are incurred.
	A lawsuit was filed against the Company’s wholly-owned subsidiary, KMG de Mexico, relating to the title to the land on which its facility in Matamoros is located. The plaintiffs claim that their title to the land is superior to the person from whom our subsidiary bought the land. The plaintiffs are seeking to have our subsidiary’s purchase overturned, and to recover the land and certain improvements or their value. The lawsuit was initially filed in 1998 in Matamoros, Mexico under Adolfo Cazares Rosas, et al vs. KMG de Mexico and Guillermo Villarreal. In January 2008, the case was sent by the appeals court back to the lower court to obtain additional factual information, and on April 20, 2009 the plaintiffs were required to re-file the case in the First Civil Court in Matamoros, Tamaulipas, Mexico as Adolfo Cazares, Luis Escudero and Juan Cue vs. KMG de Mexico and Guillermo Villarreal. In June 2011 the lower court ruled against KMG de Mexico, and held that the plaintiffs had superior title to the land, but that verdict was overturned on appeal in May 2012, and the case will be returned to the trial court for further action. The Company intends to continue to vigorously defend KMG de Mexico.
	The Company’s subsidiary in Italy has filed suit with the Provincial Tax Court in Milan, Italy to contest assessments by the taxing authority in Italy pertaining to the three year period ended July 31, 2011. In the aggregate, the amount of the assessments, including interest and penalties, is €1.7 million. If all the adjustments are sustained, the additional liability for the years 2009 through 2011 would total approximately $2.3 million, including interest and penalties through July 31, 2013 (at an exchange rate of 1.328 $/€). The Company recorded a liability for an uncertain tax position for items in the amount of $437,000. See Note 5. The Company intends to vigorously pursue its position before the court, but the ultimate outcome of this litigation is subject to uncertainty.
	In May 2013 the taxing authority in Italy assessed additional registration tax against the Company’s subsidiary in Italy based on an increased valuation of assets purchased from Air Products and Chemicals, Inc. in December 2007. The amount of the assessment, including interest and penalties through July 31, 2013, is €773,000 (or approximately $1.0 million, at an exchange rate of 1.328 $/€). The Company is negotiating the matter with the taxing authority, and the Company intends to vigorously defend its tax position. The ultimate outcome of this assessment is subject to uncertainty.
	The Company and OM Group dispute the proper calculation of the post-closing, working capital adjustment to the purchase price for the UPC subsidiaries. Each company asserts that the other owes it approximately $700,000. The parties are continuing to negotiate to resolve the dispute, but no resolution has yet been reached.
	The Company is subject to federal, state, local and foreign laws and regulations and potential liabilities relating to the protection of the environment and human health and safety including, among other things, the cleanup of contaminated sites, the treatment, storage and disposal of wastes, the emission of substances into the air or waterways, and various health and safety matters. The Company expects to incur substantial costs for ongoing compliance with such laws and regulations. The Company may also face governmental or third-party claims, or otherwise incur costs, relating to cleanup of, or for injuries resulting from, contamination at sites associated with past and present operations. The Company accrues for environmental liabilities when a determination can be made that they are probable and reasonably estimable.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Jul. 31, 2013
Employee Benefit Plans	9. EMPLOYEE BENEFIT PLANS
	The Company has a defined contribution 401(k) plan in which all regular U.S. employees are eligible to participate. The Company makes matching contributions under this plan of up to 4% of a participant’s compensation up to the annual regulated maximum amounts. The first 3% of the employee contribution is matched at 100%. The next 2% of the employee contribution is matched at 50%. Company contributions to the plan totaled approximately $457,000, $420,000 and $393,000 in fiscal years 2013, 2012 and 2011, respectively.
	The locations in the United Kingdom and Singapore, acquired as part of the UPC acquisition from OM Group, make contributions to retirement plans that function as a defined contribution retirement plans. The Company’s contributions to those plans was not significant in fiscal year 2013.
	As of July 31, 2013, the Company’s other long-term liabilities included approximately $960,000 related to benefit obligations in connection with one of its foreign subsidiaries included in the acquisition of the UPC business. This payable is an unfunded benefit obligation of the Company.
	The Company has an employee benefit arrangement for one of its former U.S. employees. As of July 31, 2013 and 2012, the associated liability was approximately $617,000 and $664,000, respectively. The amount payable is a general obligation of the Company. Benefit payments under this arrangement, which were started in April 2013, will be paid for 10 years.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Jul. 31, 2013
Earnings Per Share	10. EARNINGS PER SHARE
	Basic earnings per share have been computed by dividing net income by the weighted average shares outstanding. Diluted earnings per share have been computed by dividing net income by the weighted average shares outstanding plus potentially dilutive common shares. The following table presents information necessary to calculate basic and diluted earnings per share for periods indicated:
		Year Ended
		2013			2012			2011
		(Amounts in thousands, except per share data)
	Income from continuing operations	$	9,486		$	14,315		$	9,418
	Income/(loss) from discontinued operations		(138	)		(490	)		311
	Net income	$	9,348		$	13,825		$	9,729
	Weighted average shares outstanding — basic		11,487			11,363			11,309
	Dilutive effect of options/warrants and stock awards		91			165			180
	Weighted average shares outstanding — diluted		11,578			11,528			11,489
	Basic earnings per share
	Basic earnings per share from continuing operations	$	0.82		$	1.26		$	0.83
	Basic earnings per share on income/(loss) from discontinued operations		(0.01	)		(0.04	)		0.03
	Basic earnings per share	$	0.81		$	1.22		$	0.86
	Diluted earnings per share
	Diluted earnings per share from continuing operations	$	0.82		$	1.24		$	0.82
	Diluted earnings per share on income/(loss) from discontinued operations		(0.01	)		(0.04	)		0.03
	Diluted earnings per share	$	0.81		$	1.2		$	0.85
	Outstanding stock-based awards are not included in the computation of diluted earnings per share under the treasury stock method, if including them would be anti-dilutive. There was an average of 6,222 shares and 4,972 shares for the fiscal year ended 2013 and 2012, respectively, and less than one thousand shares of potentially dilutive securities for the fiscal year ended 2011, not included in the computation of diluted earnings per share.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Jul. 31, 2013
Stock-Based Compensation	11. STOCK-BASED COMPENSATION
	Stock-Based Incentive Plans
	The Company adopted a 2009 Long-Term Incentive Plan (“2009 LTI Plan”) in October 2009, and it was approved by the shareholders at the annual meeting in December 2009. The Company adopted a 2004 Long-Term Incentive Plan (“2004 LTI Plan”) in October 2004, and it was approved by the shareholders at the annual meeting in November 2005 (the 2009 LTI Plan and the 2004 LTI Plan are referred to collectively as the “LTI Plans”). The Company adopted the 1996 Stock Option Plan (the “1996 Stock Plan”) in October, 1996, and it was approved by the Company’s shareholders in October, 1996.
	The LTI Plans permit the granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other awards. They are administered by the Board of Directors or a committee appointed by the Board of Directors. The Board has designated the Compensation Committee as the administrator of the LTI Plans. Subject to the terms of the LTI Plans, the committee has the sole discretion to select the persons eligible to receive awards, the type and amount of incentives to be awarded, and the terms and conditions of awards. The committee also has the authority to interpret the LTI Plans, and establish and amend regulations necessary or appropriate for their administration. Any employee of the Company or a subsidiary of the Company or a director of the Company whose judgment, initiative, and efforts contributed or may be expected to contribute to the successful performance of the Company is eligible to participate. The maximum number of shares of the Company’s common stock that may be delivered pursuant to awards granted is 750,000 shares under the 2009 Long-Term Incentive Plan and 375,000 shares under the 2004 Long-Term Incentive Plan. Under the 2009 Long-Term Plan no executive officer may receive in any calendar year stock options or stock appreciation rights, or awards that are subject to the attainment of performance goals relating to more than 200,000 shares of common stock. Under the 2004 Long-Term Plan no executive officer may receive in any calendar year stock options or stock appreciation rights relating to more than 250,000 shares of common stock, or awards that are subject to the attainment of performance goals relating to more than 100,000 shares of common stock. At July 31, 2013 there were approximately 502,377 shares and 63,700 shares available for future grants under the 2009 Long-Term Plan and 2004 Long-Term Plan, respectively.
	The 1996 Stock Plan terminated by expiration of its original term on July 31, 2007. Options previously issued under the plan remain in effect. The 1996 Stock Plan is administered either by the Company’s Board of Directors or by a committee of two or more non-employee directors. The Board designated the Compensation Committee as the administrator of the plan. Options are exercisable during the period specified in each option agreement and in accordance with a vesting schedule designated by the Board of Directors or the committee. Any option agreement may provide that options become immediately exercisable in the event of a change or threatened change in control of the Company and in the event of certain mergers and reorganizations of the Company. Options may be subject to early termination within a designated period following the option holder’s cessation of service with the Company.
	Accounting for Stock-Based Compensation
	The Company recognized stock-based compensation costs of approximately $446,000, $714,000 and $542,000, respectively, for the fiscal years ended July 31, 2013, 2012 and 2011, and the related tax benefits of $168,000, $266,000 and $209,000, respectively, for the fiscal years ended July 31, 2013, 2012 and 2011. Stock-based compensation costs are recorded as selling, general and administrative expenses in the consolidated statements of income. The Company accounts for stock-based compensation costs at fair value measured on the date of grant of the award using a Black-Scholes option valuation model for stock option awards. Grant date fair value for stock awards is measured using the Company’s closing stock price on the date of grant of the stock awards where the award is based on a specific number of shares. Stock-based compensation costs are recognized as an expense over the requisite service period, generally the vesting period of the award, using the straight-line method.
	As of July 31, 2013, there was approximately $196,000 of unrecognized compensation costs that were related to outstanding stock awards expected to be recognized over a weighted-average period of 1.9 years.
	In connection with the election of Christopher T. Fraser as the Company’s President and Chief Executive Officer on September 24, 2013, the Company granted Mr. Fraser (i) 50,000 shares of common stock and (ii) time-based restricted stock awards for 30,000 shares of common stock (vesting over five years). The Company also agreed to grant performance-based restricted stock awards for an aggregate of 70,000 shares of common stock in five equal installments beginning in fiscal year 2013. The Company will record an expense of approximately $1.1 million in the first quarter of fiscal year 2014 for the grant date fair value of the 50,000 shares of common stock.
	A summary of activity for stock option and stock-awards is presented below.
	Stock Options
	A summary of option activity associated with employee compensation for the fiscal year ended July 31, 2013 is presented below.
			Shares			Weighted-
						Average
						Exercise Price
	Outstanding on August 1, 2012			180,000		$	4.13
	Granted			—			—
	Exercised			(107,000	)		4.16
	Forfeited/Expired			(15,000	)		4.37
	Outstanding on July 31, 2013			58,000		$	4.03
	The following table summarizes information about stock options outstanding at July 31, 2013 that are fully vested (currently exercisable):
			Options			Weighted-		Weighted-		Aggregate
			Outstanding and			Average		Average		Intrinsic Value
			Fully Vested			Exercise Price		Remaining		(in thousands) (1)
								Contractual
								Term (years)
	Total outstanding and fully vested			58,000		$	4.03		6.92	$	1,076
	-1	The aggregate intrinsic value is computed based on the closing price of the Company’s stock on July 31, 2013.
	No options were granted in fiscal years 2013, 2012 and 2011.
	The total intrinsic value of options exercised in fiscal years 2013, 2012 and 2011 was approximately $1.6 million, $629,000 and $546,000, respectively. The total fair value of shares vested was $39,000, $39,000 and $44,000 for the fiscal years ended 2013, 2012, and 2011, respectively.
	Performance Shares
	The Company grants performance based shares to certain executives and employees consisting of Series 1 and Series 2 awards. Stock-based compensation for the awards is recognized on a straight-line basis over the requisite service period beginning on the date of grant through the end of the measurement period based on the number of shares expected to vest at the end of the measurement period. The expected percent of vesting is determined using certain performance measures described below and is re-evaluated at the end of each reporting period through the end of the measurement period.
	At August 1, 2012 there were 227,609 non-vested performance shares outstanding. During fiscal year 2013 there were 141,059 Series 1 shares granted and there were 150,947 shares forfeited. These shares represented the maximum award subject to certain performance measures. There were 7,556 performance shares vested during fiscal year 2013. At July 31, 2013, there were 154,758 non-vested performance shares outstanding reflecting the maximum number of shares issuable under outstanding awards.
	The fair value of the fiscal year 2013 award was measured on the grant dates on December 4, 2012 using the Company’s closing stock price of $18.75. Stock-based compensation on the award is recognized on a straight-line basis over the requisite service period beginning on the date of grant through the end of the measurement period ending on July 31, 2015, based on the number of shares expected to vest at the end of the measurement period.
	A summary of the performance based stock awards granted to certain executives as Series 1 awards in fiscal year 2013 and Series 1 and Series 2 awards in fiscal years 2012 and 2011 is detailed below.
	Date of Grant		Series			Maximum		Grant Date		Measurement		Actual or
			Award			Award		Fair Value		Period Ending		Expected			Shares Projected
						(Shares)						Percentage of			to Vest or Vested (2)
												Vesting (2)
	Fiscal Year 2013 Award
	12/4/2012 (1)			Series 1			81,842	$	18.75		7/31/15		15	%		12,276
	Fiscal Year 2012 Award
	2/27/12			Series 1			300	$	18.08		7/31/14		10	%		30
	2/27/12			Series 2			200	$	18.08		7/31/14		0	%		—
							500									30
	10/28/11			Series 1			15,300	$	15.3		7/31/14		10	%		1,530
	10/28/11			Series 2			10,200	$	15.3		7/31/14		0	%		—
							25,500									1,530
	10/11/2011 (1)			Series 1			28,150	$	14.16		7/31/14		10	%		2,815
	10/11/2011 (1)			Series 2			18,766	$	14.16		7/31/14		0	%		—
							46,916									2,815
	Total						154,758									16,651
	Fiscal Year 2011 Award(2)
	12/7/2010 (1)			Series 1			37,779	$	15.65		7/31/13		20	%		7,556
	12/7/2010 (1)			Series 2			25,184	$	15.65		7/31/13		0	%		—
							62,963									7,556
	-1	Series 1 and Series 2 awards to J. Neal Butler were forfeited upon his termination of employment on July 10, 2013 and the table reflects that forfeiture. Shares forfeited included 59,217 shares granted in fiscal year 2013, 30,837 Series 1 and 20,558 Series 2 awards granted in fiscal year 2012, and 24,201 Series 1 and 16,134 Series 2 awards granted in fiscal year 2011.
	-2	For performance shares granted in December 2010, the above table represents the actual percentage vesting and shares vested as of the end of the measurement period ended July 31, 2013. For the other performance share grants identified in the above table, the information set forth is the expected vesting percentage and the shares projected to vest.
	Series 1: Vesting for the Series 1 awards is subject to a performance requirement composed of certain revenue growth objectives and average annual return on invested capital or equity objectives measured across a three-year period. For the fiscal year 2013 and 2012 awards, the expected percentage of vesting is based on performance through July 31, 2013 and reflects the percentage of shares projected to vest for the respective awards at the end of their measurement periods. For the Series 1 award for fiscal year 2011, the actual vesting was determined to be 20% at the end of the measurement period. Performance shares that have vested are normally issued within 75 days of the end of the fiscal year.
	Series 2: Vesting for the Series 2 awards is subject to performance requirements pertaining to the growth rate in the Company’s basic earnings per share over a three-year period. For the fiscal year 2012 awards the expected percentage of vesting is based on performance through July 31, 2013 and reflects the percentage of shares projected to vest for the respective awards at the end of their measurement periods. For the Series 2 award for fiscal year 2011, the actual vesting was determined to be zero at the end of the measurement period. Performance shares that have vested are normally issued within 75 days of the end of the fiscal year.
	The weighted-average grant-date fair value of performance share awards forfeited during the fiscal year 2013 was $16.36. The weighted-average grant-date fair value of performance share awards outstanding at August 1, 2012 and July 31, 2013 was $15.10 and $17.66, respectively.
	The total fair value of performance shares vested during fiscal years 2013, 2012 and 2011 was approximately $118,000, $297,000, and $63,000, respectively.
	Time-Based Shares
	A summary of activity for time-based stock awards for the fiscal year ended July 31, 2013 is presented below:
		Shares			Weighted-Average
					Grant-Date
					Fair Value
Non-vested on August 1, 2012			5,769		$	15.65
Granted (1)			24,896			19.4
Vested (2)			(28,688	)		18.91
Forfeited			(1,977	)		15.65
Non-vested on July 31, 2013			—
-1	Reflects the aggregate number of shares granted to non-employee directors during fiscal year 2013. The awards were granted for each three month service period ended on August 31, 2012, November 30, 2012, February 28, 2013 and May 31, 2013. The awards were granted on August 28, 2012, December 4, 2012, February 26, 2013 and May 21, 2013 and vested on the date of grant. The Company recognizes compensation expense related to the awards over the respective three month service period in accordance with GAAP.
-2	Includes 24,896 shares granted to non-employee directors indicated above and 3,792 shares granted to employees.
The total fair value of shares vested during the fiscal year ended 2013, 2012 and 2011 was approximately $542,000, $545,000, and $374,000, respectively.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Jul. 31, 2013
Discontinued Operations	12. DISCONTINUED OPERATIONS
	Discontinued operations reflected a loss before income taxes of $203,000 and $711,000 for fiscal years 2013 and 2012, respectively, and income before taxes of $514,000 for fiscal year 2011.
	In fiscal year 2008, the Company discontinued operations of its herbicide product line that had comprised the agricultural chemical segment. The Company incurred costs of $121,000, $599,000 and $120,000 in the fiscal years ended July 31, 2013, 2012 and 2011, respectively, for dismantling the herbicide facility and for medical and other expenses associated with an accident that occurred in fiscal year 2012 while the facility was being dismantled.
	On March 1, 2012, the Company sold the business that had comprised the animal health segment to Bayer Healthcare LLC. For the fiscal year ended July 31, 2013 and 2012, $82,000 and $112,000 was reported as a loss from discontinued operations before income taxes. In fiscal year 2013 the loss included $57,000 for a post-closing inventory adjustment that was recognized as loss on sale of the business in the first fiscal quarter, and in fiscal year 2012 the loss included the gain on sale of approximately $90,000.
	In the sale of the animal health business $1.0 million of the price is restricted cash held in escrow. The escrowed amount is to be held pending final acceptance by the EPA of certain studies being performed at the request of the EPA on tetrachlorvinphos, the active ingredient used in Rabon products. The escrowed funds are to be released to the Company once the EPA has finally accepted the studies, the buyer has voluntarily canceled the products, or after five years. The escrowed funds are to be released to the buyer if the EPA cancels the products to which the studies pertain before the funds are distributed to the Company.
	Animal health net sales and income before income tax reported in discontinued operations were as follows for the fiscal year ended July 31:
		2013			2012			2011
		(Amounts in thousands)
	Revenue	$	57		$	5,643		$	10,760
	Income (loss) before income taxes		(25	)		(202	)		634

Segment_Information

Segment Information	12 Months Ended
	Jul. 31, 2013
Segment Information	13. SEGMENT INFORMATION
	The Company has two reportable segments - electronic chemicals and wood treating chemicals. The electronic chemicals segment includes the ultra pure chemicals business acquired from OM Group on May 31, 2013. The Company evaluated the segment criteria in accordance with GAAP and concluded that its existing electronic chemicals business and the recently acquired ultra pure chemicals business met the criteria of a single operating segment.
			2013			2012			2011
			(Amounts in thousands)
	Sales
	Electronic chemicals		$	165,755		$	159,451		$	151,481
	Wood treating			97,185			113,034			104,115
	Total sales for reportable segments		$	262,940		$	272,485		$	255,596
	Depreciation and amortization
	Electronic chemicals		$	7,416		$	5,933		$	5,607
	Wood treating			418			504			814
	Discontinued operations			—			342			664
	Other — general corporate			461			239			269
	Total consolidated depreciation and amortization		$	8,295		$	7,018		$	7,354
	Segment income from operations (1)
	Electronic chemicals		$	13,992		$	13,392		$	6,205
	Wood treating			10,522			15,622			14,766
	Total segment income from operations		$	24,514		$	29,014		$	20,971
	Capital expenditures
	Electronic chemicals		$	48,421		$	4,493		$	7,359
	Wood treating			396			393			354
	Discontinued operations			—			—			17
	Included in UPC acquisition			(43,793	)		—			—
	Other — general corporate			481			307			538
	Total capital expenditures		$	5,505		$	5,193		$	8,268
	Total assets
	Electronic chemicals		$	193,135		$	111,144		$	114,929
	Wood treating			50,880			44,880			45,917
	Total assets for reportable segments		$	244,015		$	156,024		$	160,846
	-1	Segment income from operations includes allocated corporate overhead expenses.
	Corporate overhead expenses allocated to segment income for the fiscal years ended July 31, 2013, 2012 and 2011 were as follows:
			2013			2012			2011
			(Amounts in thousands)
	Electronic chemicals		$	5,218		$	5,354		$	4,066
	Wood treating			4,461			4,406			3,337
	Total corporate overhead expense allocation		$	9,679		$	9,760		$	7,403
	For fiscal years 2013, 2012 and 2011 sales to one customer in our electronic chemicals segment represented approximately 20%, 19% and 16%, respectively of the Company’s net sales, and sales to one customer in our wood treating segment represented approximately 16%, 12% and 12% of the Company’s net sales. No other customers accounted for 10% or more of the Company’s net sales.
	A reconciliation of total segment to consolidated amounts as of July 31, 2013 and 2012, and for fiscal years 2013, 2012 and 2011 is set forth in the table below.
			2013			2012			2011
			(Amounts in thousands)
	Assets:
	Total assets for reportable segments		$	244,015		$	156,024
	Total assets for discontinued operations (1)			467			467
	Other current assets			9,120			3,627
	Other assets			8,413			7,572
	Total assets		$	262,015		$	167,690
	Sales:
	Total sales for reportable segments		$	262,940		$	272,485		$	255,596
	Other (2)			371			215			—
	Net sales		$	263,311		$	272,700		$	255,596
	Segment income from operations:
	Total segment income from operations(3)		$	24,514		$	29,014		$	20,971
	Other corporate expense(3)			(7,334	)		(3,577	)		(3,949	)
	Operating income			17,180			25,437			17,022
	Interest expense, net			(1,771	)		(2,099	)		(2,335	)
	Other expense, net			(208	)		(269	)		(208	)
	Income from continuing operations before income taxes		$	15,201		$	23,069		$	14,479
	Geographic Data
			2013			2012			2011
			(Amounts in thousands)
	Net sales:
	United States		$	200,184		$	229,140		$	218,961
	International			63,127			43,560			36,635
	Net sales		$	263,311		$	272,700		$	255,596
Property, plant and equipment, net:
United States		$	51,720		$	52,178
International			44,968			15,848
Property, plant and equipment, net		$	96,688		$	68,026
-1	Reflects deferred tax assets as of July 31, 2013 and 2012.
-2	Primarily reflects fees from the transition services agreement in connection with the sale of the animal health business. The agreement terminated on March 1, 2013. See Note 12.
-3	Other corporate expense primarily represents employee stock-based compensation expenses and those expenses associated with the Company’s operation as a public entity such as board compensation, audit expense, fees related to the listing of our stock and expenses incurred to pursue acquisition opportunities. The amounts presented for fiscal years 2012 and 2011 include corporate overhead previously allocated to the animal health business. These amounts were not reallocated to the remaining segments.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Jul. 31, 2013
Selected Quarterly Financial Data (Unaudited)	14. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
	Quarterly results for the fiscal years ended July 31, 2013 and 2012 exclude the effect of discontinued operations, except for net income amounts. See note 12 for further detail on discontinued operations.
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(Amounts in thousands, except per share data)
	Year Ended July 31, 2013
	Net sales	$	65,336	$	56,959	$	59,929	$	81,087
	Gross profit		20,088		15,721		16,333		24,328
	Operating income		7,104		3,196		4,355		2,525
	Income from continuing operations before income taxes		6,643		2,725		3,918		1,915
	Net income		4,142		1,618		2,865		723
	Earnings Per share:
	Income per share from continuing operations
	- basic	$	0.36	$	0.14	$	0.25	$	0.07
	- diluted		0.36		0.14		0.25		0.07
	Net income per share
	- basic		0.36		0.14		0.25		0.06
	- diluted		0.36		0.14		0.25		0.06
	Year Ended July 31, 2012
	Net sales	$	71,539	$	66,975	$	66,579	$	67,607
	Gross profit		18,675		17,141		20,606		20,643
	Operating income		6,991		4,883		6,868		6,695
	Income from continuing operations before income taxes		6,366		4,256		6,316		6,131
	Net income		3,535		2,462		3,965		3,863
	Earnings Per share:
	Income per share from continuing operations
	- basic	$	0.34	$	0.22	$	0.34	$	0.35
	- diluted		0.34		0.22		0.33		0.34
	Net income per share
	- basic		0.31		0.22		0.35		0.34
	- diluted		0.31		0.21		0.34		0.33
	Earnings per share amounts are computed independently for each quarter presented. Therefore, the sum of the quarterly earnings per share may not equal annual earnings per share.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Jul. 31, 2013
Schedule II - Valuation and Qualifying Accounts	KMG Chemicals, Inc.
	Schedule II — Valuation and Qualifying Accounts
	Fiscal years ended July 31, 2013, 2012 and 2011
	Description	Balance at		Charged to costs			Additions/			Balance at
		beginning		and expenses			Deductions			end
		of period								of period
	Year ended July 31, 2013:
	Allowance for doubtful accounts	$	16,000	$	208,000		$	—		$	224,000
	Inventory obsolescence		493,000		(107,000	)		-420,000			180,000
	Valuation allowance on deferred tax assets		—		—			—			—
	Year ended July 31, 2012:
	Allowance for doubtful accounts	$	414,000	$	—		$	(398,000	)	$	16,000
	Inventory obsolescence		333,000		272,000			(112,000	)		493,000
	Valuation allowance on deferred tax assets		—		—			—			—
	Year ended July 31, 2011:
	Allowance for doubtful accounts	$	260,000	$	154,000		$	—		$	414,000
	Inventory obsolescence		418,000		(34,000	)		(51,000	)		333,000
	Valuation allowance on deferred tax assets		627,000		(627,000	)		—			—

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2013
General	General — KMG Chemicals, Inc. (the “Company”) is involved principally in the manufacture, formulation and distribution of specialty chemicals in carefully focused markets through its two wholly-owned subsidiaries, KMG Electronic Chemicals, Inc. (“KMG EC”) and KMG-Bernuth, Inc. (“KMG Bernuth”).
	In its electronic chemicals business, the Company sells high purity wet process chemicals to the semiconductor industry, and in the wood treating chemicals business the Company sells two industrial wood treating chemicals, pentachlorophenol (“penta”) and creosote. The Company operates its electronic chemicals business through KMG EC in North America and through KMG Italia, S.r.l. (“KMG Italia”) and KMG Electronic Chemicals Holdings S.a.r.l (“KMG Lux”) (and its subsidiaries) in Europe and elsewhere. That business has facilities in the United States, the United Kingdom, France, Italy and Singapore. In the wood treating business the Company manufactures penta at its plant in Matamoros, Mexico through KMG de Mexico (“KMEX”), a Mexican corporation which is a wholly-owned subsidiary of KMG Bernuth. The Company sells its wood treating chemicals in the United States, Mexico and Canada. The electronic chemicals and wood treating businesses constitute two reportable segments that the Company considers of equal importance. See Note 13.
Principles of Consolidation	Principles of Consolidation — The consolidated financial statements include the accounts of KMG Chemicals, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates — The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Reclassifications	Reclassifications — Certain reclassifications of prior year amounts have been made to conform to current year presentation.
Cash and Cash Equivalents	Cash and Cash Equivalents — The Company considers all investments with original maturities of three months or less when purchased to be cash equivalents. The Company reduces cash balances when checks are disbursed. Due to the time delay in checks clearing the banks, the Company reports a negative balance in its cash disbursement accounts as a current liability which is reflected as book overdraft in the consolidated balance sheets. The Company did not have a negative cash balance as of July 31, 2013.
Restricted Cash	Restricted Cash — Restricted cash includes cash balances which are legally or contractually restricted to use. The Company’s restricted cash as of July 31, 2013 and 2012 includes proceeds that were placed in escrow in connection with the sale of the animal health business. See Note 12.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The carrying value of financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of the relatively short maturity of these instruments. The fair value of the Company’s debt at July 31, 2013 and 2012 approximated its carrying value since the debt obligations bear interest at a rate consistent with market rates.
Accounts Receivable	Accounts Receivable — The Company’s trade accounts receivable are primarily from wood-treating customers and from electronic chemical customers worldwide. The Company extends credit based on an evaluation of the customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is dependent on each customer’s financial condition. At July 31, 2013 there were two customers that represented approximately 12% and 14%, respectively of the Company’s accounts receivable, and at July 31, 2012 there were two customers that represented approximately 12% and 17%, respectively, of the Company’s accounts receivable.
	The Company records an allowance for doubtful accounts to reduce accounts receivable when the Company believes an account may not be collected. A provision for bad debt expense is recorded to selling, general and administrative expenses. The amount of bad debt expense recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a customer-by-customer analyses of accounts receivable balances each period and our assessment of future bad debt exposure. Historically, write offs of accounts receivable balances have been insignificant. The allowance was $224,000 and $16,000 at July 31, 2013 and 2012, respectively.
Inventories	Inventories — Inventories are valued at the lower of cost or market. For certain products, cost is generally determined using the first-in, first-out (“FIFO”) method. For certain other products the Company utilizes a weighted-average cost. The Company records inventory obsolescence as a reduction in its inventory when considered unsellable.
Property, Plant, and Equipment	Property, Plant, and Equipment — Property, plant, and equipment are stated at cost less accumulated depreciation and amortization. Major renewals and betterments are capitalized. Repairs and maintenance costs are expensed as incurred.
	Depreciation for equipment commences once placed in service, and depreciation for buildings and leasehold improvements commences once they are ready for their intended use. Depreciable life is determined through economic analysis. Depreciation for financial statement purposes is provided on the straight-line method.
	The estimated useful lives of classes of assets are as follows:
	Asset Class	Life (Years)
	Building	15 to 30
	Plant	10 to 18
	Equipment	3 to 15
	Leasehold improvements	remaining life
		of the lease
	Depreciation expense was approximately $7.7 million, $6.5 million and $6.3 million in fiscal years 2013, 2012 and 2011, respectively.
Intangible Assets	Intangible Assets — Identifiable intangible assets with a defined life are amortized using a straight-line or accelerated method over the useful lives of the assets. Identifiable intangible assets of an indefinite life are not amortized. These assets are required to be tested for impairment at least annually. If this review indicates that impairment has occurred, the Company’s carrying value of intangibles will be adjusted to fair value. Based on an assessment of qualitative factors, in accordance with GAAP, it was determined that there were no events or circumstances that would lead the Company to a determination that is more likely than not that the fair value of the applicable assets was less than its carrying value as of July 31, 2013 and 2012. The Company concluded that as a result its indefinite lived intangible assets were not impaired as of July 31, 2013 and 2012. It is the Company’s policy to expense costs as incurred in connection with the renewal or extension of its intangible assets.
Goodwill	Goodwill — The Company has goodwill of $3.8 million and $7.1 million, respectively, associated with its wood treating and electronic chemicals segments. The carrying value of the Company’s goodwill is reviewed at least annually, and if this review indicates that it will not be recoverable the Company’s carrying value of goodwill will be adjusted to fair value. Based on an assessment of qualitative factors it was determined that there were no events or circumstances that would lead the Company to a determination that is more likely than not that the fair value of the applicable reporting unit was less than its carrying value as of July 31, 2013 and 2012. Accordingly, the Company determined that as of July 31, 2013 and 2012, goodwill was not impaired. As a result, there was no change in the carrying value of goodwill as of July 31, 2013 and 2012, respectively, except for an increase in goodwill of $7.1 million in connection with the acquisition of the electronic chemicals business subsidiaries of OM Group, Inc. See Note 2.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets — Long-lived assets, including property, plant and equipment, and intangible assets with defined lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its disposition. The measurement of an impairment loss for long-lived assets, where management expects to hold and use the asset, are based on the asset’s estimated fair value. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value.
Revenue Recognition	Revenue Recognition — The Company’s chemical products are sold in the open market and revenue is recognized when risk of loss and title to the products transfers to customers. In general, risk of loss transfers upon shipment to customers. The Company also recognizes service revenue in connection with technical support services and chemicals delivery and handling at customer facilities. Revenue is recognized as those services are provided.
Cost of Sales	Cost of Sales — Cost of sales includes inbound freight charges, purchasing and receiving costs, depreciation, inspection costs and internal transfer costs. In the case of products manufactured by the Company, direct and indirect manufacturing costs (including depreciation and amortization) and associated plant administrative expenses are included as well as laid-in cost of raw materials consumed in the manufacturing process.
Distribution Expenses	Distribution Expenses — These expenses include outbound freight, depreciation, storage and handling expenses and other miscellaneous costs (including depreciation and amortization) associated with product storage, handling and distribution.
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses — These expenses include selling expenses, corporate headquarters’ expenses, amortization of intangible assets and environmental regulatory support expenses.
Advertising Costs	Advertising Costs — Our policy is to expense advertising costs as they are incurred. Advertising costs were approximately $26,000, $347,000 and $608,000 in fiscal years ended July 31, 2013, 2012 and 2011, respectively. These costs were primarily related to the animal health business which is reported as discontinued operations in the consolidated statements of income. See Note 12.
Shipping and Handling Costs	Shipping and Handling Costs — Shipping and handling costs are included in cost of sales and distribution expenses. Inbound freight charges and internal transfer costs are included in cost of sales. Product storage and handling costs and the cost of distributing products to the Company’s customers are included in distribution expenses.
Income Taxes	Income Taxes — The Company files a consolidated United States federal income tax return, and for financial reporting purposes, provides income taxes for the differences between the financial statement carrying amounts of assets and liabilities and their tax bases in accordance with GAAP. See Note 5.
Earnings Per Share	Earnings Per Share — Basic earnings per common share amounts are calculated using the average number of common shares outstanding during each period. Diluted earnings per share assumes the issuance of restricted stock awards and the exercise of stock options having exercise prices less than the average market price during the period of the common stock, using the treasury stock method.
Foreign Currency Translation	Foreign Currency Translation — The functional currency of the Company’s Mexico operations is the U.S. Dollar. As a result, monetary assets and liabilities for KMEX are re-measured to U.S. dollars at current rates at the balance sheet dates, income statement items are re-measured at the average monthly exchange rates for the dates those items were recognized, and certain assets (including plant and production equipment) are re-measured at historical exchange rates. Foreign currency transaction gains and losses are included in the statement of operations as incurred along with gains and losses from currency re-measurement. These gains and losses were nominal in fiscal years 2013, 2012 and 2011.
	The Company’s international operations in the electronic chemicals business are in Europe and Singapore, and use local currencies as the functional currency, including the GB Pound, Euro and Singapore Dollar. The translation adjustment resulting from currency translation of the local currency into the reporting currency (U.S. Dollar) is included as a separate component of stockholders’ equity. The assets and liabilities have been translated from local currencies into U.S. Dollars using exchange rates in effect at the balance sheet dates. Results of operations have been translated using the average exchange rates during the period. Foreign currency translation resulted in a translation adjustment gains of $1.8 million and $2.1 million in fiscal years 2013 and 2011, respectively, and a loss of $3.1 million in fiscal years 2012, each of which are included in accumulated other comprehensive loss in the consolidated balance sheets.
Stock-Based Compensation	Stock-Based Compensation — The Company’s stock-based compensation expense is based on the fair value of the award measured on the date of grant. For stock option awards, the grant date fair value is measured using a Black-Scholes option valuation model. For stock awards, the Company’s stock price on the date of the grant is used to measure grant date fair value. For awards of stock which are based on a fixed monetary value the grant date fair value is based on the monetary value. Stock-based compensation costs are recognized as an expense over the requisite service period of the award using the straight-line method.
Recent Accounting Standards	Recent Accounting Standards
	The Company has considered all recently issued accounting standards updates and SEC rules and interpretive releases.
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a similar Tax Loss, or a Tax Credit Carryforward Exists.” The update was issued to reduce the diversity in presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The update requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions listed in the update. The new presentation requirements are effective for interim and annual periods beginning after December 15, 2013. Since this update only affects presentation of unrecognized tax benefits in financial statements, adoption of this standard is not expected to have a material impact on the Company’s financial statements.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Jul. 31, 2013
Estimated Useful Lives of Classes of Assets	The estimated useful lives of classes of assets are as follows:
	Asset Class	Life (Years)
	Building	15 to 30
	Plant	10 to 18
	Equipment	3 to 15
	Leasehold improvements	remaining life
		of the lease

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Jul. 31, 2013
Summary of Acquired Assets and Assumed Liabilities and Preliminary Acquisition Accounting for Fair Value of Assets and Liabilities Recognized	The following table summarizes the acquired assets and assumed liabilities and the preliminary acquisition accounting for the fair value of the assets and liabilities recognized in the consolidated balance sheets at the acquisition date (in thousands):
	Cash	$	689
	Accounts receivable		14,698
	Inventory		11,047
	Other current assets		1,963
	Property, plant and equipment		28,939
	Intangible assets:
	Value of product qualifications		12,800
	Non-compete agreement		1,900
	Transition services		154
	Total intangible assets		14,854
	Total assets acquired	$	72,190
	Current liabilities		11,401
	Other long-term liabilities		5,326
	Total liabilities assumed		16,727
	Net assets acquired	$	55,463
Unaudited Pro forma Financial Information	The following table sets forth pro forma results for the fiscal years ended July 31, 2013 and 2012 had the acquisition occurred as of the beginning of fiscal year 2012. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations would have been had we completed the acquisition as of the dates indicated.
		(Unaudited) (in  thousands,
		except per share data)
		2013		2012
	Revenues	$	340,427	$	366,882
	Operating income		15,955		26,083
	Net income		9,123		13,056
	Earnings per share — basic	$	0.79	$	1.15

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Jul. 31, 2013
Inventories	Inventories are summarized as follows at July 31, 2013 and 2012 (in thousands):
		2013			2012
	Raw materials and supplies	$	8,003		$	5,846
	Work in process		1,382			896
	Supplies		1,730			1,405
	Finished products		42,452			33,007
	Less reserve for inventory obsolescence		(180	)		(493	)
	Inventories, net	$	53,387		$	40,661

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	12 Months Ended
	Jul. 31, 2013
Property, Plant and Equipment and Related Accumulated Depreciation and Amortization	Property, plant, and equipment and related accumulated depreciation and amortization are summarized as follows at July 31, 2013 and 2012 (in thousands):
		2013			2012
	Land	$	15,620		$	9,034
	Buildings and improvements		41,273			35,578
	Equipment		66,807			45,924
	Leasehold improvements		143			143
			123,843			90,679
	Less accumulated depreciation and amortization		(36,933	)		(28,824	)
			86,910			61,855
	Construction-in-progress		9,778			6,171
	Property, plant and equipment, net	$	96,688		$	68,026

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2013
Geographical Sources of Income from Continuing Operations Before Income Taxes	The Company is subject to United States federal, state and foreign taxes on its operations. The geographical sources of income from continuing operations before income taxes for each of the three years ended July 31 are as follows (in thousands):
		2013			2012			2011
	United States	$	12,033		$	21,789		$	13,716
	Foreign		3,168			1,280			763
	Income from continuing operations before income taxes	$	15,201		$	23,069		$	14,479
Components of Income Tax Expense (Benefit) from Continuing Operations	The components of income tax expense/(benefit) from continuing operations for the years ended July 31 consisted of the following (in thousands):
		2013			2012			2011
	Current:
	Federal	$	2,833		$	5,639		$	1,746
	Foreign		1,437			686			513
	State		197			1,071			719
			4,467			7,396			2,978
	Deferred:
	Federal		1,426			1,441			2,546
	Foreign		(282	)		(104	)		(648	)
	State		104			21			185
			1,248			1,358			2,083
	Total	$	5,715		$	8,754		$	5,061
Deferred Tax Assets and Liabilities	The following table presents the components of the Company’s deferred tax assets and liabilities at July 31, 2013 and 2012 (in thousands):
		2013			2012
	Deferred tax assets:
	Current deferred tax assets:
	Bad debt expense	$	259		$	—
	Inventory		920			780
	Accrued liabilities		590			460
	Accrued bonus		295			710
	Other		46			27
	Total current deferred tax assets	$	2,110		$	1,977
	Non-current deferred tax assets
	Net operating loss	$	803		$	411
	Difference in amortization basis of intangibles		363			—
	Difference in depreciable basis of property		731			745
	Deferred compensation		793			690
	Other		—			5
	Total non-current deferred tax assets	$	2,690		$	1,851
	Deferred tax liabilities:
	Current deferred tax liabilities:
	Other		(148	)		—
	Prepaid assets		(562	)		(560	)
	Total current deferred tax liabilities:	$	(710	)	$	(560	)
	Non-current deferred tax liabilities:
	Difference in amortization basis of intangibles	$	(6,370	)	$	(2,440	)
	Difference in depreciable basis of property		(6,713	)		(5,328	)
	Total non-current deferred tax liabilities		(13,083	)		(7,768	)
	Net current deferred tax asset	$	1,400		$	1,417
	Net non-current deferred tax liability	$	(10,393	)	$	(5,917	)
Difference Between Actual Tax Provision	The following table accounts for the differences between the actual tax provision, and the amounts obtained by applying the applicable statutory United States federal income tax rate of 35% to income from continuing operations before income taxes for each of the years ended July 31, 2013, 2012, and 2011, respectively (in thousands):
		2013			2012			2011
	Income taxes at the federal statutory rate	$	5,320		$	8,074		$	5,068
	Effect of foreign operations		(65	)		160			225
	Change in valuation allowance		—			—			(627	)
	State income taxes, net of federal income tax effect		232			717			659
	Acquisition related cost		714			—			—
	Other		(486	)		(197	)		(264	)
	Total	$	5,715		$	8,754		$	5,061

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Jul. 31, 2013
Intangible Assets	Intangible assets are summarized as follows (in thousands):
		Number of Years
		Weighted		July 31, 2013
		Average
		Amortization		Original		Accumulated			Carrying
		Period		Cost		Amortization			Amount
	Intangible assets subject to amortization
	(range of useful life):
	Electronic chemicals-related contracts (5-8 years)		6.5	$	2,297	$	(253	)	$	2,044
	Electronic chemicals-related trademarks and patents (10-15 years)		12		117		(57	)		60
	Electronic chemicals-value of product qualifications (5-15 years)		14.1		14,100		(1,047	)		13,053
	Total intangible assets subject to amortization		13	$	16,514	$	(1,357	)		15,157
	Intangible assets not subject to amortization:
	Creosote product registrations									5,339
	Penta product registrations									8,765
	Total intangible assets not subject to amortization									14,104
	Total intangible assets, net								$	29,261
		Number of Years
		Weighted		July 31, 2012
		Average
		Amortization		Original		Accumulated			Carrying
		Period		Cost		Amortization			Amount
	Intangible assets subject to amortization
	(range of useful life):
	Creosote supply contract (10 years)		10	$	4,000	$	(4,000	)	$	—
	Electronic chemicals-related contracts (3-8 years)		3.8		1,164		(1,053	)		111
	Electronic chemicals-related trademarks and patents (10-15 years)		12		117		(46	)		71
	Electronic chemicals—value of product qualifications (5 years)		5		1,300		(606	)		694
	Total intangible assets subject to amortization		8	$	6,581	$	(5,705	)		876
	Intangible assets not subject to amortization:
	Creosote product registrations									5,339
	Penta product registrations									8,765
	Total intangible assets not subject to amortization									14,104
	Total intangible assets, net								$	14,980

LongTerm_Obligations_Tables

Long-Term Obligations (Tables)	12 Months Ended
	Jul. 31, 2013
Long-Term Debt and Current Maturities	The Company’s long-term debt and current maturities as of July 31, 2013 and July 31, 2012 consisted of the following (in thousands):
		July 31,			July 31,
		2013			2012
	Senior Secured Debt:
	Note Purchase Agreement, maturing on December 31, 2014, interest rate of 7.43%	$	20,000		$	20,000
	Revolving Loan Facility, maturing on April 30, 2018, variable interest rates based on LIBOR plus 1.50% and 2.0% at July 31, 2013 and 2012, respectively		65,000			4,000
	Total debt		85,000			24,000
	Current maturities of long-term debt		—			—
	Long-term debt, net of current maturities	$	85,000		$	24,000
Ratio of Funded Debt to EBITDA	The revolving loan bears interest at varying rate of LIBOR plus a margin based on funded debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”), as described in the table.
	Ratio of Funded Debt to EBITDA	Margin
	Equal to or greater than 2.5 to 1.0		2.25	%
	Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0		2	%
	Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0		1.75	%
	Less than 1.5 to 1.0		1.5	%
Principal Payments Due Under Long-term Debt Agreements	Principal payments due under long-term debt agreements for the fiscal years ended July 31 are as follows (in thousands):
		Total			2014		2015		2016		2017		2018		Thereafter
	Long-term debt	$	85,000		$	—	$	20,000	$	—	$	—	$	65,000	$	—

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Jul. 31, 2013
Future Payments Under Certain Contractual Obligations	Our obligations to make future payments under certain contractual obligations as of July 31, 2013 are summarized in the following table (in thousands):
			Total		2014		2015		2016		2017		2018		Thereafter
	Operating leases		$	11,942	$	3,748	$	1,775	$	1,493	$	1,119	$	752	$	3,055
	Purchase obligations (1)			189,508		70,283		48,322		40,751		28,037		2,115		—
	Total		$	201,450	$	74,031	$	50,097	$	42,244	$	29,156	$	2,867	$	3,055
	-1	Consists primarily of raw materials purchase contracts. These are typically not fixed price arrangements. The prices are based on the prevailing market prices.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Jul. 31, 2013
Basic and Diluted Earnings Per Share	The following table presents information necessary to calculate basic and diluted earnings per share for periods indicated:
		Year Ended
		2013			2012			2011
		(Amounts in thousands, except per share data)
	Income from continuing operations	$	9,486		$	14,315		$	9,418
	Income/(loss) from discontinued operations		(138	)		(490	)		311
	Net income	$	9,348		$	13,825		$	9,729
	Weighted average shares outstanding — basic		11,487			11,363			11,309
	Dilutive effect of options/warrants and stock awards		91			165			180
	Weighted average shares outstanding — diluted		11,578			11,528			11,489
	Basic earnings per share
	Basic earnings per share from continuing operations	$	0.82		$	1.26		$	0.83
	Basic earnings per share on income/(loss) from discontinued operations		(0.01	)		(0.04	)		0.03
	Basic earnings per share	$	0.81		$	1.22		$	0.86
	Diluted earnings per share
	Diluted earnings per share from continuing operations	$	0.82		$	1.24		$	0.82
	Diluted earnings per share on income/(loss) from discontinued operations		(0.01	)		(0.04	)		0.03
	Diluted earnings per share	$	0.81		$	1.2		$	0.85

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Jul. 31, 2013
Stock Option Activity Associated with Employee Compensation	A summary of option activity associated with employee compensation for the fiscal year ended July 31, 2013 is presented below.
			Shares			Weighted-
						Average
						Exercise Price
	Outstanding on August 1, 2012			180,000		$	4.13
	Granted			—			—
	Exercised			(107,000	)		4.16
	Forfeited/Expired			(15,000	)		4.37
	Outstanding on July 31, 2013			58,000		$	4.03
Stock Options Outstanding And Fully Vested	The following table summarizes information about stock options outstanding at July 31, 2013 that are fully vested (currently exercisable):
			Options			Weighted-		Weighted-		Aggregate
			Outstanding and			Average		Average		Intrinsic Value
			Fully Vested			Exercise Price		Remaining		(in thousands) (1)
								Contractual
								Term (years)
	Total outstanding and fully vested			58,000		$	4.03		6.92	$	1,076
	-1	The aggregate intrinsic value is computed based on the closing price of the Company’s stock on July 31, 2013.
Summary of Performance Based Stock Awards Granted	A summary of the performance based stock awards granted to certain executives as Series 1 awards in fiscal year 2013 and Series 1 and Series 2 awards in fiscal years 2012 and 2011 is detailed below.
	Date of Grant		Series			Maximum		Grant Date		Measurement		Actual or
			Award			Award		Fair Value		Period Ending		Expected			Shares Projected
						(Shares)						Percentage of			to Vest or Vested (2)
												Vesting (2)
	Fiscal Year 2013 Award
	12/4/2012 (1)			Series 1			81,842	$	18.75		7/31/15		15	%		12,276
	Fiscal Year 2012 Award
	2/27/12			Series 1			300	$	18.08		7/31/14		10	%		30
	2/27/12			Series 2			200	$	18.08		7/31/14		0	%		—
							500									30
	10/28/11			Series 1			15,300	$	15.3		7/31/14		10	%		1,530
	10/28/11			Series 2			10,200	$	15.3		7/31/14		0	%		—
							25,500									1,530
	10/11/2011 (1)			Series 1			28,150	$	14.16		7/31/14		10	%		2,815
	10/11/2011 (1)			Series 2			18,766	$	14.16		7/31/14		0	%		—
							46,916									2,815
	Total						154,758									16,651
	Fiscal Year 2011 Award(2)
	12/7/2010 (1)			Series 1			37,779	$	15.65		7/31/13		20	%		7,556
	12/7/2010 (1)			Series 2			25,184	$	15.65		7/31/13		0	%		—
							62,963									7,556
	-1	Series 1 and Series 2 awards to J. Neal Butler were forfeited upon his termination of employment on July 10, 2013 and the table reflects that forfeiture. Shares forfeited included 59,217 shares granted in fiscal year 2013, 30,837 Series 1 and 20,558 Series 2 awards granted in fiscal year 2012, and 24,201 Series 1 and 16,134 Series 2 awards granted in fiscal year 2011.
	-2	For performance shares granted in December 2010, the above table represents the actual percentage vesting and shares vested as of the end of the measurement period ended July 31, 2013. For the other performance share grants identified in the above table, the information set forth is the expected vesting percentage and the shares projected to vest.
Summary of Activity for Time-Based Stock Awards	A summary of activity for time-based stock awards for the fiscal year ended July 31, 2013 is presented below:
			Shares			Weighted-Average
						Grant-Date
						Fair Value
	Non-vested on August 1, 2012			5,769		$	15.65
	Granted (1)			24,896			19.4
	Vested (2)			(28,688	)		18.91
	Forfeited			(1,977	)		15.65
	Non-vested on July 31, 2013			—
	-1	Reflects the aggregate number of shares granted to non-employee directors during fiscal year 2013. The awards were granted for each three month service period ended on August 31, 2012, November 30, 2012, February 28, 2013 and May 31, 2013. The awards were granted on August 28, 2012, December 4, 2012, February 26, 2013 and May 21, 2013 and vested on the date of grant. The Company recognizes compensation expense related to the awards over the respective three month service period in accordance with GAAP.
	-2	Includes 24,896 shares granted to non-employee directors indicated above and 3,792 shares granted to employees.
	The total fair value of shares vested during the fiscal year ended 2013, 2012 and 2011 was approximately $542,000, $545,000, and $374,000, respectively.

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Jul. 31, 2013
Sales and Income Before Income Tax Reported in Discontinued Operations	Animal health net sales and income before income tax reported in discontinued operations were as follows for the fiscal year ended July 31:
		2013			2012			2011
		(Amounts in thousands)
	Revenue	$	57		$	5,643		$	10,760
	Income (loss) before income taxes		(25	)		(202	)		634

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Jul. 31, 2013
Revenues and Assets
			2013			2012			2011
			(Amounts in thousands)
	Sales
	Electronic chemicals		$	165,755		$	159,451		$	151,481
	Wood treating			97,185			113,034			104,115
	Total sales for reportable segments		$	262,940		$	272,485		$	255,596
	Depreciation and amortization
	Electronic chemicals		$	7,416		$	5,933		$	5,607
	Wood treating			418			504			814
	Discontinued operations			—			342			664
	Other — general corporate			461			239			269
	Total consolidated depreciation and amortization		$	8,295		$	7,018		$	7,354
	Segment income from operations (1)
	Electronic chemicals		$	13,992		$	13,392		$	6,205
	Wood treating			10,522			15,622			14,766
	Total segment income from operations		$	24,514		$	29,014		$	20,971
	Capital expenditures
	Electronic chemicals		$	48,421		$	4,493		$	7,359
	Wood treating			396			393			354
	Discontinued operations			—			—			17
	Included in UPC acquisition			(43,793	)		—			—
	Other — general corporate			481			307			538
	Total capital expenditures		$	5,505		$	5,193		$	8,268
	Total assets
	Electronic chemicals		$	193,135		$	111,144		$	114,929
	Wood treating			50,880			44,880			45,917
	Total assets for reportable segments		$	244,015		$	156,024		$	160,846
	-1	Segment income from operations includes allocated corporate overhead expenses.
Overhead Expenses Allocated to Segment Income	Corporate overhead expenses allocated to segment income for the fiscal years ended July 31, 2013, 2012 and 2011 were as follows:
			2013			2012			2011
			(Amounts in thousands)
	Electronic chemicals		$	5,218		$	5,354		$	4,066
	Wood treating			4,461			4,406			3,337
	Total corporate overhead expense allocation		$	9,679		$	9,760		$	7,403
Reconciliation of total segment to consolidated amounts	A reconciliation of total segment to consolidated amounts as of July 31, 2013 and 2012, and for fiscal years 2013, 2012 and 2011 is set forth in the table below.
			2013			2012			2011
			(Amounts in thousands)
	Assets:
	Total assets for reportable segments		$	244,015		$	156,024
	Total assets for discontinued operations (1)			467			467
	Other current assets			9,120			3,627
	Other assets			8,413			7,572
	Total assets		$	262,015		$	167,690
	Sales:
	Total sales for reportable segments		$	262,940		$	272,485		$	255,596
	Other (2)			371			215			—
	Net sales		$	263,311		$	272,700		$	255,596
	Segment income from operations:
	Total segment income from operations(3)		$	24,514		$	29,014		$	20,971
	Other corporate expense(3)			(7,334	)		(3,577	)		(3,949	)
	Operating income			17,180			25,437			17,022
	Interest expense, net			(1,771	)		(2,099	)		(2,335	)
	Other expense, net			(208	)		(269	)		(208	)
	Income from continuing operations before income taxes		$	15,201		$	23,069		$	14,479
Geographic data	Geographic Data
			2013			2012			2011
			(Amounts in thousands)
	Net sales:
	United States		$	200,184		$	229,140		$	218,961
	International			63,127			43,560			36,635
	Net sales		$	263,311		$	272,700		$	255,596
	Property, plant and equipment, net:
	United States		$	51,720		$	52,178
	International			44,968			15,848
	Property, plant and equipment, net		$	96,688		$	68,026
	-1	Reflects deferred tax assets as of July 31, 2013 and 2012.
	-2	Primarily reflects fees from the transition services agreement in connection with the sale of the animal health business. The agreement terminated on March 1, 2013. See Note 12.
	-3	Other corporate expense primarily represents employee stock-based compensation expenses and those expenses associated with the Company’s operation as a public entity such as board compensation, audit expense, fees related to the listing of our stock and expenses incurred to pursue acquisition opportunities. The amounts presented for fiscal years 2012 and 2011 include corporate overhead previously allocated to the animal health business. These amounts were not reallocated to the remaining segments.

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Jul. 31, 2013
Selected Quarterly Financial Data
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
		(Amounts in thousands, except per share data)
	Year Ended July 31, 2013
	Net sales	$	65,336	$	56,959	$	59,929	$	81,087
	Gross profit		20,088		15,721		16,333		24,328
	Operating income		7,104		3,196		4,355		2,525
	Income from continuing operations before income taxes		6,643		2,725		3,918		1,915
	Net income		4,142		1,618		2,865		723
	Earnings Per share:
	Income per share from continuing operations
	- basic	$	0.36	$	0.14	$	0.25	$	0.07
	- diluted		0.36		0.14		0.25		0.07
	Net income per share
	- basic		0.36		0.14		0.25		0.06
	- diluted		0.36		0.14		0.25		0.06
	Year Ended July 31, 2012
	Net sales	$	71,539	$	66,975	$	66,579	$	67,607
	Gross profit		18,675		17,141		20,606		20,643
	Operating income		6,991		4,883		6,868		6,695
	Income from continuing operations before income taxes		6,366		4,256		6,316		6,131
	Net income		3,535		2,462		3,965		3,863
	Earnings Per share:
	Income per share from continuing operations
	- basic	$	0.34	$	0.22	$	0.34	$	0.35
	- diluted		0.34		0.22		0.33		0.34
	Net income per share
	- basic		0.31		0.22		0.35		0.34
	- diluted		0.31		0.21		0.34		0.33

Recovered_Sheet1

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
	Segment	Customer
	Product
	Customer
Schedule Of Significant Accounting Policies [Line Items]
Number of industrial wood treating chemicals products	2
Number of reportable segments	2
Number of customers representing a significant portion of accounts receivable	2	2
Allowance for accounts receivable	$224,000	$16,000
Depreciation expense	7,700,000	6,500,000	6,300,000
Goodwill	10,929,000	3,778,000
Advertising costs	26,000	347,000	608,000
Foreign currency translation resulting in gains (loss)	1,800,000	-3,100,000	2,100,000
Wood Treating
Schedule Of Significant Accounting Policies [Line Items]
Goodwill	3,800,000
Electronic Chemicals
Schedule Of Significant Accounting Policies [Line Items]
Goodwill	7,100,000
Increase in goodwill	$7,100,000
First Customer
Schedule Of Significant Accounting Policies [Line Items]
Percentage of accounts receivable for significant customer	12.00%	12.00%
Second Customer
Schedule Of Significant Accounting Policies [Line Items]
Percentage of accounts receivable for significant customer	14.00%	17.00%

Estimated_Useful_Lives_of_Clas

Estimated Useful Lives of Classes of Assets (Detail)	12 Months Ended
	Jul. 31, 2013
Building | Minimum
Property, Plant and Equipment [Line Items]
Useful lives of assets	15 years
Building | Maximum
Property, Plant and Equipment [Line Items]
Useful lives of assets	30 years
Plant | Minimum
Property, Plant and Equipment [Line Items]
Useful lives of assets	10 years
Plant | Maximum
Property, Plant and Equipment [Line Items]
Useful lives of assets	18 years
Equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful lives of assets	3 years
Equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful lives of assets	15 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Useful life of leasehold	remaining life of the lease

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended					12 Months Ended					12 Months Ended
	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	31-May-13	31-May-13	Jul. 31, 2013
												Revolving Loan Facility	Revolving Loan Facility	Revised Credit Facility	Revised Credit Facility	Om Group Incorporation	Om Group Incorporation	Om Group Incorporation	Performance Products And Solutions
												Secured Debt	Secured Debt					Revolving Loan Facility
																		Secured Debt
Business Acquisition [Line Items]
Business acquisition, cash paid																	$63,300,000
Business acquisition, working capital adjustment																	684,000
Long-term debt	85,000,000				24,000,000				85,000,000	24,000,000		65,000,000	4,000,000					65,000,000
Business acquisition, goodwill																	7,100,000
Net sales	81,087,000	59,929,000	56,959,000	65,336,000	67,607,000	66,579,000	66,975,000	71,539,000	263,311,000	272,700,000	255,596,000					16,000,000
Net income	723,000	2,865,000	1,618,000	4,142,000	3,863,000	3,965,000	2,462,000	3,535,000	9,348,000	13,825,000	9,729,000					979,000
Integration costs related to acquisition																			577,000
Interest expense related to the revised credit facility														1,000,000	1,600,000
Acquisition-related costs incurred									2,100,000
Depreciation and amortization									$3,100,000	$3,300,000

Summary_of_Acquired_Assets_and

Summary of Acquired Assets and Assumed Liabilities and Preliminary Acquisition Accounting for Fair Value of Assets Recognized (Detail) (USD $)	Jul. 31, 2013
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Cash	$689
Accounts receivable	14,698
Inventory	11,047
Other current assets	1,963
Property, plant and equipment	28,939
Intangible assets:
Value of product qualifications	12,800
Non-compete agreement	1,900
Transition services	154
Total intangible assets	14,854
Total assets acquired	72,190
Current liabilities	11,401
Other long-term liabilities	5,326
Total liabilities assumed	16,727
Net assets acquired	$55,463

Unaudited_Pro_forma_Financial_

Unaudited Pro forma Financial Information (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenues	$340,427	$366,882
Operating income	15,955	26,083
Net income	$9,123	$13,056
Earnings per share - basic	$0.79	$1.15

Inventories_Detail

Inventories (Detail) (USD $)	Jul. 31, 2013	Jul. 31, 2012
In Thousands, unless otherwise specified
Inventory Net [Line Items]
Raw materials and supplies	$8,003	$5,846
Work in process	1,382	896
Supplies	1,730	1,405
Finished products	42,452	33,007
Less reserve for inventory obsolescence	-180	-493
Inventories, net	$53,387	$40,661

Property_Plant_and_Equipment_a

Property, Plant, and Equipment and Related Accumulated Depreciation and Amortization (Detail) (USD $)	Jul. 31, 2013	Jul. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Land	$15,620	$9,034
Buildings and improvements	41,273	35,578
Equipment	66,807	45,924
Leasehold improvements	143	143
Property, plant and equipment, gross	123,843	90,679
Less accumulated depreciation and amortization	-36,933	-28,824
Property, plant and equipment, total	86,910	61,855
Construction-in-progress	9,778	6,171
Property, plant and equipment, net	$96,688	$68,026

Geographical_Sources_of_Income

Geographical Sources of Income from Continuing Operations Before Income Taxes (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Components Of Earnings Loss Before Income Taxes [Line Items]
United States									$12,033	$21,789	$13,716
Foreign									3,168	1,280	763
Income from continuing operations before income taxes	$1,915	$3,918	$2,725	$6,643	$6,131	$6,316	$4,256	$6,366	$15,201	$23,069	$14,479

Components_of_Income_Tax_Expen

Components of Income Tax Expense (Benefit) from Continuing Operations (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Current:
Federal	$2,833	$5,639	$1,746
Foreign	1,437	686	513
State	197	1,071	719
Total current	4,467	7,396	2,978
Deferred:
Federal	1,426	1,441	2,546
Foreign	-282	-104	-648
State	104	21	185
Total deferred	1,248	1,358	2,083
Total	$5,715	$8,754	$5,061

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Income tax benefit/(expense)	$65,000	$221,000	($203,000)
Income tax examination liability of Italy subsidiary	1,600,000
Liability for uncertain tax positions in Italy	437,000
Recognition of tax benefit	5,715,000	8,754,000	5,061,000
Undistributed earnings of Mexico subsidiary	5,600,000
Federal income tax rate	35.00%	35.00%	35.00%
Foreign
Net operating loss carryforwards with no expiration date	3,800,000
American Taxpayer Relief Act Of Two Thousand Twelve
Recognition of tax benefit	($200,000)
U K
United Kingdom corporation tax rate	21.00%

Deferred_Tax_Assets_and_Liabil

Deferred Tax Assets and Liabilities (Detail) (USD $)	Jul. 31, 2013	Jul. 31, 2012
In Thousands, unless otherwise specified
Current deferred tax assets:
Bad debt expense	$259
Inventory	920	780
Accrued liabilities	590	460
Accrued bonus	295	710
Other	46	27
Total current deferred tax assets	2,110	1,977
Non-current deferred tax assets
Net operating loss	803	411
Difference in amortization basis of intangibles	363
Difference in depreciable basis of property	731	745
Deferred compensation	793	690
Other		5
Total non-current deferred tax assets	2,690	1,851
Current deferred tax liabilities:
Other	-148
Prepaid assets	-562	-560
Total current deferred tax liabilities	-710	-560
Non-current deferred tax liabilities:
Difference in amortization basis of intangibles	-6,370	-2,440
Difference in depreciable basis of property	-6,713	-5,328
Total non-current deferred tax liabilities	-13,083	-7,768
Net current deferred tax asset	1,400	1,417
Net non-current deferred tax liability	($10,393)	($5,917)

Differences_Between_Actual_Tax

Differences Between Actual Tax Provision and Amounts Obtained by Applying Applicable United States Tax Rate (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Schedule Of Income Taxes [Line Items]
Income taxes at the federal statutory rate	$5,320	$8,074	$5,068
Effect of foreign operations	-65	160	225
Change in valuation allowance			-627
State income taxes, net of federal income tax effect	232	717	659
Acquisition related cost	714
Other	-486	-197	-264
Total	$5,715	$8,754	$5,061

Intangible_Assets_Detail

Intangible Assets (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	31-May-13	Jul. 31, 2013	Jul. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, net		$29,261	$14,980
Minimum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		15 years
Creosote product registrations
Finite-Lived Intangible Assets [Line Items]
Total intangible assets not subject to amortization		5,339	5,339
Penta product registrations
Finite-Lived Intangible Assets [Line Items]
Total intangible assets not subject to amortization		8,765	8,765
Total intangible assets not subject to amortization
Finite-Lived Intangible Assets [Line Items]
Total intangible assets not subject to amortization		14,104	14,104
Creosote supply contract
Finite-Lived Intangible Assets [Line Items]
Range of useful life			10 years
Number of Years Weighted Average Amortization Period			10 years
Original Cost			4,000
Accumulated Amortization			-4,000
Electronic chemicals-related contracts
Finite-Lived Intangible Assets [Line Items]
Range of useful life	7 years
Number of Years Weighted Average Amortization Period		6 years 6 months	3 years 9 months 18 days
Original Cost		2,297	1,164
Accumulated Amortization		-253	-1,053
Carrying Amount		2,044	111
Electronic chemicals-related contracts | Minimum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		5 years	3 years
Electronic chemicals-related contracts | Maximum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		8 years	8 years
Electronic chemicals-related trademarks and patents
Finite-Lived Intangible Assets [Line Items]
Number of Years Weighted Average Amortization Period		12 years	12 years
Original Cost		117	117
Accumulated Amortization		-57	-46
Carrying Amount		60	71
Electronic chemicals-related trademarks and patents | Minimum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		10 years	10 years
Electronic chemicals-related trademarks and patents | Maximum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		15 years	15 years
Electronic chemicals-value of product qualifications
Finite-Lived Intangible Assets [Line Items]
Range of useful life	15 years		5 years
Number of Years Weighted Average Amortization Period		14 years 1 month 6 days	5 years
Original Cost		14,100	1,300
Accumulated Amortization		-1,047	-606
Carrying Amount		13,053	694
Electronic chemicals-value of product qualifications | Minimum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		5 years
Electronic chemicals-value of product qualifications | Maximum
Finite-Lived Intangible Assets [Line Items]
Range of useful life		15 years
Amortizable Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Number of Years Weighted Average Amortization Period		13 years	8 years
Original Cost		16,514	6,581
Accumulated Amortization		-1,357	-5,705
Carrying Amount		$15,157	$876

Intangible_Asset_Additional_In

Intangible Asset - Additional Information (Detail) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2011

Jul. 31, 2013

Jul. 31, 2013

31-May-13

Jul. 31, 2012

Jul. 31, 2013

Jul. 31, 2013

31-May-13

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2013

Jul. 31, 2012

Minimum

Maximum

Electronic chemicals-value of product qualifications

Electronic chemicals-value of product qualifications

Electronic chemicals-value of product qualifications

Electronic chemicals-value of product qualifications

Electronic chemicals-related contracts

Electronic chemicals-related contracts

Electronic chemicals-related contracts

Electronic chemicals-related contracts

Electronic chemicals-related contracts

Minimum

Maximum

Minimum

Minimum

Maximum

Maximum

Estimated useful lives of intangible assets

5 years

15 years

15 years

5 years

5 years

15 years

7 years

5 years

3 years

8 years

8 years

Amortization expense

$573,000

$548,000

$1,000,000

Estimated amortization expense for fiscal years 2014

1,700,000

Estimated amortization expense for fiscal years 2015

1,500,000

Estimated amortization expense for fiscal years 2016

1,300,000

Estimated amortization expense for fiscal years 2017

1,300,000

Estimated amortization expense for fiscal years 2018

1,200,000

Acquired intangible assets

$12,800,000

$1,900,000

LongTerm_Obligations_Additiona

Long-Term Obligations - Additional Information (Detail) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Debt Instrument [Line Items]
Deferred financing costs	$229,000
Long-term debt	85,000,000	24,000,000
Ratio of funded debt to EBITDA maximum	3
Ratio of funded debt to EBITDA minimum	1
Fixed charge coverage ratio maximum	1.5
Fixed charge coverage ratio minimum	1
Current ratio	150.00%
Revolving Loan Facility
Debt Instrument [Line Items]
Line Of Credit Facility, outstanding	65,000,000
Line Of Credit Facility additional borrowing capacity	41,600,000
Reduction credit capacity due to unused letters of credit	3,400,000
Amount available under revolving facility	18,700,000
Amount to be borrowed under revolving loan facility	110,000,000
Reduction in revolving loan commitment	40,000,000
Deferred financing costs	229,000
Revolving Loan Facility | Maximum
Debt Instrument [Line Items]
Percentage of unused commitment fee on unused amount of commitments under revolving loan facility	0.35%
Revolving Loan Facility | Minimum
Debt Instrument [Line Items]
Percentage of unused commitment fee on unused amount of commitments under revolving loan facility	0.25%
Revolving Loan Facility | Issuance of Debt
Debt Instrument [Line Items]
Line Of Credit Facility additional revolving loan increase	25,000,000
Loan maturity date	30-Apr-18
Each year from September 30, 2014 to September 30, 2017 | Revolving Loan Facility
Debt Instrument [Line Items]
Reduction in revolving loan commitment	10,000,000
Senior Secured Debt | Note Purchase Agreement
Debt Instrument [Line Items]
Loan maturity date	31-Dec-14
Long-term debt	20,000,000	20,000,000
Note purchase agreement interest rate	7.43%
Secured Debt | Revolving Loan Facility
Debt Instrument [Line Items]
Loan maturity date	30-Apr-18
Debt instrument variable rate	1.69%	2.20%
Long-term debt	$65,000,000	$4,000,000

LongTerm_Debt_and_Current_Matu

Long-Term Debt and Current Maturities (Detail) (USD $)	Jul. 31, 2013	Jul. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Total debt	$85,000	$24,000
Current maturities of long-term debt
Long-term debt, net of current maturities	85,000	24,000
Senior Secured Debt | Note Purchase Agreement
Debt Instrument [Line Items]
Total debt	20,000	20,000
Secured Debt | Revolving Loan Facility
Debt Instrument [Line Items]
Total debt	$65,000	$4,000

LongTerm_Debt_and_Current_Matu1

Long-Term Debt and Current Maturities (Parenthetical) (Detail)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Senior Secured Debt | Note Purchase Agreement
Debt Instrument [Line Items]
Loan maturity date	31-Dec-14
Note purchase agreement interest rate	7.43%
Secured Debt | Revolving Loan Facility
Debt Instrument [Line Items]
Loan maturity date	30-Apr-18
Variable interest rate	LIBOR plus 1.50	LIBOR plus 2.0%

Ratio_of_Funded_Debt_to_Ebitda

Ratio of Funded Debt to Ebitda (Detail)	12 Months Ended
	Jul. 31, 2013
Equal to or greater than 2.5 to 1.0
Debt Instrument [Line Items]
Margin	2.25%
Equal to or greater than 2.5 to 1.0 | Minimum
Debt Instrument [Line Items]
Ratio of Funded Debt to EBITDA	2.5
Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0
Debt Instrument [Line Items]
Margin	2.00%
Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0 | Minimum
Debt Instrument [Line Items]
Ratio of Funded Debt to EBITDA	2
Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0 | Maximum
Debt Instrument [Line Items]
Ratio of Funded Debt to EBITDA	2.5
Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0
Debt Instrument [Line Items]
Margin	1.75%
Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0 | Minimum
Debt Instrument [Line Items]
Ratio of Funded Debt to EBITDA	1.5
Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0 | Maximum
Debt Instrument [Line Items]
Ratio of Funded Debt to EBITDA	2
Less than 1.5 to 1.0
Debt Instrument [Line Items]
Margin	1.50%
Less than 1.5 to 1.0 | Maximum
Debt Instrument [Line Items]
Ratio of Funded Debt to EBITDA	1.5

Principal_Payments_Due_Under_L

Principal Payments Due Under Long-Term Debt Agreements (Detail) (USD $)	Jul. 31, 2013	Jul. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Long-term debt, net of current maturities	$85,000	$24,000
2015	20,000
2018	65,000
Thereafter

Future_Payments_Under_Certain_

Future Payments Under Certain Contractual Obligation (Detail) (USD $)	Jul. 31, 2013
In Thousands, unless otherwise specified
Contractual Obligation [Line Items]
Operating leases, total	$11,942
Operating leases, first year	3,748
Operating leases, second year	1,775
Operating leases, third year	1,493
Operating leases, fourth year	1,119
Operating leases, fifth year	752
Operating leases, thereafter	3,055
Purchase obligation, total	189,508	[1]
Purchase obligation, first year	70,283	[1]
Purchase obligation, second year	48,322	[1]
Purchase obligation, third year	40,751	[1]
Purchase obligation, fourth year	28,037	[1]
Purchase obligation, fifth year	2,115	[1]
Purchase obligation, thereafter		[1]
Contractual obligation, total	201,450
Contractual obligation, first year	74,031
Contractual obligation, second year	50,097
Contractual obligation, third year	42,244
Contractual obligation, fourth year	29,156
Contractual obligation, fifth year	2,867
Contractual obligation, thereafter	$3,055
[1]	Consists primarily of raw materials purchase contracts. These are typically not fixed price arrangements. The prices are based on the prevailing market prices.

Recovered_Sheet2

Commitments and Contingencies - Additional Information (Detail)	12 Months Ended				1 Months Ended
	Jul. 31, 2013	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2013	Jul. 31, 2013
	USD ($)	EUR (€)	USD ($)	USD ($)	Air Products and Chemicals, Inc	Air Products and Chemicals, Inc
					USD ($)	EUR (€)
Commitments and Contingencies [Line Items]
Rent expenses related to operating leases	$2,700,000		$2,300,000	$2,000,000
FIFRA research and testing programs expenses	522,000		802,000	760,000
Proposed adjustment from taxing authorities resulting additional income tax	2,300,000	1,700,000			1,000,000	773,000
Foreign currency exchange rate, translation	1.328	1.328
Liability for uncertain tax positions in Italy	437,000
Post-closing, working capital adjustment	$700,000

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Defined Contribution Plan Disclosure [Line Items]
Percent of contribution made under plan	4.00%
Contribution made under plan	$457,000	$420,000	$393,000
Benefit obligations in connection with foreign subsidiaries included in the acquisition of the UPC business	-960,000
Liability under employee benefit arrangement	$617,000	$664,000
Employee Benefit arrangement monthly payments start period	2013-04
The term of general obligation	10 years
First 3 Percent of Each Participant's Contributions
Defined Contribution Plan Disclosure [Line Items]
Defined Contribution Plan Employer Matching Contribution Percent Of Match	100.00%
Next Two Percent Contribution
Defined Contribution Plan Disclosure [Line Items]
Defined Contribution Plan Employer Matching Contribution Percent Of Match	50.00%

Basic_and_Diluted_Earnings_Per

Basic and Diluted Earnings Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Components Of Basic And Diluted Earning Per Share [Line Items]
Income from continuing operations									$9,486	$14,315	$9,418
Income/(loss) from discontinued operations									-138	-490	311
Net income	$723	$2,865	$1,618	$4,142	$3,863	$3,965	$2,462	$3,535	$9,348	$13,825	$9,729
Weighted average shares outstanding - basic									11,487	11,363	11,309
Dilutive effect of options/warrants and stock awards									91	165	180
Weighted average shares outstanding - diluted									11,578	11,528	11,489
Basic earnings per share
Basic earnings per share from continuing operations	$0.07	$0.25	$0.14	$0.36	$0.35	$0.34	$0.22	$0.34	$0.82	$1.26	$0.83
Basic earnings per share on income/(loss) from discontinued operations									($0.01)	($0.04)	$0.03
Basic earnings per share	$0.06	$0.25	$0.14	$0.36	$0.34	$0.35	$0.22	$0.31	$0.81	$1.22	$0.86
Diluted earnings per share
Diluted earnings per share from continuing operations	$0.07	$0.25	$0.14	$0.36	$0.34	$0.33	$0.22	$0.34	$0.82	$1.24	$0.82
Diluted earnings per share on income/(loss) from discontinued operations									($0.01)	($0.04)	$0.03
Diluted earnings per share	$0.06	$0.25	$0.14	$0.36	$0.33	$0.34	$0.21	$0.31	$0.81	$1.20	$0.85

Earnings_per_Share_Additional_

Earnings per Share - Additional Information (Detail)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
			Maximum
Computation Of Earnings Per Share Line Items
Number of shares potentially dilutive securities not included in the computation of diluted earnings per share	6,222	4,972	1,000

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2011

Jul. 31, 2013

Jul. 31, 2012

Feb. 27, 2012

Oct. 28, 2011

Oct. 11, 2011

Jul. 31, 2011

Dec. 07, 2010

Dec. 04, 2012

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2011

Jul. 31, 2011

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2011

Sep. 24, 2013

Sep. 24, 2013

Sep. 24, 2013

Sep. 24, 2013

Sep. 24, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Jul. 31, 2013

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Performance Shares

Outstanding Stock Option

Series 1

Series 1

Series 2

Time Based Shares

Time Based Shares

Time Based Shares

Subsequent Event

President And Chief Executive Officer

President And Chief Executive Officer

President And Chief Executive Officer

President And Chief Executive Officer

2009 long term incentive plan

2009 long term incentive plan

2004 long term incentive plan

2004 long term incentive plan

2004 long term incentive plan

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Executive Officer

Executive Officer

Executive Officer

Common Stock

Time Based Restricted Stock Awards

Performance Based Restricted Stock Awards

Maximum

Maximum

Maximum

Installment

Stock Appreciation Rights (SARs)

Stock Appreciation Rights (SARs)

Performance Shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock related to performance goal

750,000

200,000

375,000

250,000

100,000

Shares available for future grant

502,377

63,700

Recognized stock based compensation cost

$446,000

$714,000

$542,000

Share based compensation, related tax benefits

168,000

266,000

209,000

Unrecognized compensation costs related to outstanding stock awards

196,000

Weighted average period for recognition of compensation cost

1 year 10 months 24 days

Share based compensation award grants in period

154,758

500

25,500

46,916

62,963

24,896

[1]

50,000

30,000

70,000

Share based compensation award number of installments

5

Share based compensation award vesting period

5 years

Share based compensation not yet recognized

1,100,000

Total intrinsic value of option exercised

1,600,000

629,000

546,000

Total fair value of options vested

39,000

39,000

44,000

Performance shares outstanding, non vested

154,758

227,609

5,769

Share based compensation award grants in period gross of forfeiture

141,059

Awards vested

7,556

16,651

[2]

30

[2]

1,530

[2]

2,815

[2]

7,556

[2]

28,688

[3]

Performance based stock awards forfeited

150,947

1,977

Closing stock price

$18.75

Share based payment award, expiration date

31-Jul-15

Vesting percentage of awards

20.00%

0.00%

Performance shares issued period

75 days

75 days

Grant Date Fair Value

$17.66

$15.10

$15.65

Weighted average grant date fair value of performance share awards forfeited

$16.36

$15.65

Total fair value of shares vested

$118,000

$297,000

$63,000

$542,000

$545,000

$374,000

[1]

Reflects the aggregate number of shares granted to non-employee directors during fiscal year 2013. The awards were granted for each three month service period ended on August 31, 2012, November 30, 2012, February 28, 2013 and May 31, 2013. The awards were granted on August 28, 2012, December 4, 2012, February 26, 2013 and May 21, 2013 and vested on the date of grant. The Company recognizes compensation expense related to the awards over the respective three month service period in accordance with GAAP.

[2]

For performance shares granted in December 2010, the above table represents the actual percentage vesting and shares vested as of the end of the measurement period ended July 31, 2013. For the other performance share grants identified in the above table, the information set forth is the expected vesting percentage and the shares projected to vest.

[3]

Includes 24,896 shares granted to non-employee directors indicated above and 3,792 shares granted to employees.

Stock_Option_Activity_Associat

Stock Option Activity Associated with Employee Compensation (Detail) (USD $)	12 Months Ended
	Jul. 31, 2013
Shares
Outstanding on August 1, 2012	180,000
Granted
Exercised	-107,000
Forfeited/Expired	-15,000
Outstanding on July 31, 2013	58,000
Weighted Average Exercise Price
Outstanding on August 1, 2012	$4.13
Granted
Exercised	$4.16
Forfeited/Expired	$4.37
Outstanding on July 31, 2013	$4.03

Stock_Options_Outstanding_And_

Stock Options Outstanding And Fully Vested (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jul. 31, 2013
Options Outstanding and Fully Vested
Total outstanding and fully vested	58,000
Weighted-Average Exercise Price
Total outstanding and fully vested	$4.03
Weighted-Average Remaining Contractual Term (years)
Total outstanding and fully vested	6 years 11 months 1 day
Aggregate Intrinsic Value
Total outstanding and fully vested	$1,076	[1]
[1]	The aggregate intrinsic value is computed based on the closing price of the Company's stock on July 31, 2013.

Summary_of_Performance_Based_S

Summary of Performance Based Stock Awards Granted (Detail) (Performance Shares, USD $)

12 Months Ended

Jul. 31, 2013

Jul. 31, 2012

Feb. 27, 2012

Oct. 28, 2011

Oct. 11, 2011

Dec. 07, 2010

Dec. 04, 2012

Feb. 27, 2012

Oct. 28, 2011

Oct. 11, 2011

Dec. 07, 2010

Feb. 27, 2012

Oct. 28, 2011

Oct. 11, 2011

Dec. 07, 2010

Series Award One

Series Award One

Series Award One

Series Award One

Series Award One

Series Award Two

Series Award Two

Series Award Two

Series Award Two

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Grant Dates

4-Dec-12

[1]

27-Feb-12

28-Oct-11

11-Oct-11

[1]

7-Dec-10

[1],[2]

27-Feb-12

28-Oct-11

11-Oct-11

[1]

7-Dec-10

[1],[2]

Maximum Award (Shares)

154,758

500

25,500

46,916

62,963

81,842

[1]

300

15,300

28,150

[1]

37,779

[1],[2]

200

10,200

18,766

[1]

25,184

[1],[2]

Grant Date Fair Value

$18.75

[1]

$18.08

$15.30

$14.16

[1]

$15.65

[1],[2]

$18.08

$15.30

$14.16

[1]

$15.65

[1],[2]

Measurement Period Ending

31-Jul-15

[1]

31-Jul-14

31-Jul-14

31-Jul-14

[1]

31-Jul-13

[1],[2]

31-Jul-14

31-Jul-14

31-Jul-14

[1]

31-Jul-13

[1],[2]

Actual or Expected Percentage of Vesting

15.00%

[1],[2]

10.00%

[2]

10.00%

[2]

10.00%

[1],[2]

20.00%

[1],[2]

0.00%

[2]

0.00%

[2]

0.00%

[1],[2]

0.00%

[1],[2]

Actual Shares Vested or Shares Projected to Vest

7,556

16,651

[2]

30

[2]

1,530

[2]

2,815

[2]

7,556

[2]

12,276

[1],[2]

30

[2]

1,530

[2]

2,815

[1],[2]

7,556

[1],[2]

[1]

Series 1 and Series 2 awards to J. Neal Butler were forfeited upon his termination of employment on July 10, 2013 and the table reflects that forfeiture. Shares forfeited included 59,217 shares granted in fiscal year 2013, 30,837 Series 1 and 20,558 Series 2 awards granted in fiscal year 2012, and 24,201 Series 1 and 16,134 Series 2 awards granted in fiscal year 2011.

[2]

For performance shares granted in December 2010, the above table represents the actual percentage vesting and shares vested as of the end of the measurement period ended July 31, 2013. For the other performance share grants identified in the above table, the information set forth is the expected vesting percentage and the shares projected to vest.

Summary_of_Performance_Based_S1

Summary of Performance Based Stock Awards Granted (Parenthetical) (Detail) (Executive Officer)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2013	Jul. 31, 2011	Jul. 31, 2012	Jul. 31, 2011
		Series Award One	Series Award One	Series Award Two	Series Award Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based payment, forfeitures in period	59,217	30,837	24,201	20,558	16,134

Summary_of_Activity_for_TimeBa

Summary of Activity for Time-Based Stock Awards (Detail) (Time Based Shares, USD $)	12 Months Ended
	Jul. 31, 2013
Time Based Shares
Non-vested Shares
Non-vested on August 1, 2012	5,769
Granted	24,896	[1]
Vested	-28,688	[2]
Forfeited	-1,977
Weighted-Average Grant-Date Fair Value
Non-vested on August 1, 2012	$15.65
Granted	$19.40	[1]
Vested	$18.91	[2]
Forfeited	$15.65
[1]	Reflects the aggregate number of shares granted to non-employee directors during fiscal year 2013. The awards were granted for each three month service period ended on August 31, 2012, November 30, 2012, February 28, 2013 and May 31, 2013. The awards were granted on August 28, 2012, December 4, 2012, February 26, 2013 and May 21, 2013 and vested on the date of grant. The Company recognizes compensation expense related to the awards over the respective three month service period in accordance with GAAP.
[2]	Includes 24,896 shares granted to non-employee directors indicated above and 3,792 shares granted to employees.

Summary_of_Activity_for_TimeBa1

Summary of Activity for Time-Based Stock Awards (Parenthetical) (Detail) (Time Based Shares)	12 Months Ended
	Jul. 31, 2013		31-May-13	Feb. 28, 2013	Nov. 30, 2012	Aug. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date			21-May-13	26-Feb-13	4-Dec-12	28-Aug-12
Time based stock awards granted	24,896	[1]
Non Employee Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time based stock awards granted	24,896
Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time based stock awards granted	3,792
[1]	Reflects the aggregate number of shares granted to non-employee directors during fiscal year 2013. The awards were granted for each three month service period ended on August 31, 2012, November 30, 2012, February 28, 2013 and May 31, 2013. The awards were granted on August 28, 2012, December 4, 2012, February 26, 2013 and May 21, 2013 and vested on the date of grant. The Company recognizes compensation expense related to the awards over the respective three month service period in accordance with GAAP.

Discontinued_Operations_Additi

Discontinued Operations - Additional Information (Detail) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Mar. 01, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations before income taxes	($203,000)	($711,000)	$514,000
Animal Health Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations before income taxes	-25,000	-202,000	634,000
Restricted cash held in escrow related to business sale				1,000,000
Animal Health Segment | Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Period of escrow deposit release	5 years
Bayer Healthcare Llc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations before income taxes	-82,000	-112,000
Post closing adjustment costs	57,000
Gain on sale		90,000
Herbicide Product Line
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations before income taxes	-203,000	-711,000	514,000
Dismantling of related equipment and the accident cost	$121,000	$599,000	$120,000

Sales_and_Income_Before_Income

Sales and Income Before Income Tax Reported in Discontinued Operations (Detail) (USD $)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) before income taxes	($203,000)	($711,000)	$514,000
Animal Health Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	57,000	5,643,000	10,760,000
Income (loss) before income taxes	($25,000)	($202,000)	$634,000

Segment_Information_Additional

Segment Information - Additional Information (Detail)	12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Segment Reporting Information [Line Items]
Number of reportable segment	2
Maximum Percentage of Revenue Generated From Other Customer	10.00%
Electronic Chemicals
Segment Reporting Information [Line Items]
Revenue generated from single external customer	20.00%	19.00%	16.00%
Wood Treating
Segment Reporting Information [Line Items]
Revenue generated from single external customer	16.00%	12.00%	12.00%

Segment_Information_Detail

Segment Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2013		Jul. 31, 2012		Jul. 31, 2011
Segment Reporting Information [Line Items]
Net sales	$81,087	$59,929	$56,959	$65,336	$67,607	$66,579	$66,975	$71,539	$263,311		$272,700		$255,596
Total consolidated depreciation and amortization									8,295		7,018		7,354
Total segment income from operations	2,525	4,355	3,196	7,104	6,695	6,868	4,883	6,991	17,180		25,437		17,022
Total capital expenditures									5,505		5,193		8,268
Total assets for reportable segments	262,015				167,690				262,015		167,690
Electronic Chemicals
Segment Reporting Information [Line Items]
Net sales									165,755		159,451		151,481
Total consolidated depreciation and amortization									7,416		5,933		5,607
Total segment income from operations									13,992	[1]	13,392	[1]	6,205	[1]
Total capital expenditures									48,421		4,493		7,359
Total assets for reportable segments	193,135				111,144				193,135		111,144		114,929
Wood Treating
Segment Reporting Information [Line Items]
Net sales									97,185		113,034		104,115
Total consolidated depreciation and amortization									418		504		814
Total segment income from operations									10,522	[1]	15,622	[1]	14,766	[1]
Total capital expenditures									396		393		354
Total assets for reportable segments	50,880				44,880				50,880		44,880		45,917
Reportable Segments
Segment Reporting Information [Line Items]
Net sales									262,940		272,485		255,596
Total segment income from operations									24,514	[1],[2]	29,014	[1],[2]	20,971	[1],[2]
Total assets for reportable segments	244,015				156,024				244,015		156,024		160,846
Discontinued Operations
Segment Reporting Information [Line Items]
Total consolidated depreciation and amortization											342		664
Total capital expenditures													17
Other - general corporate
Segment Reporting Information [Line Items]
Total consolidated depreciation and amortization									461		239		269
Total capital expenditures									481		307		538
Included In UPC Acquisition
Segment Reporting Information [Line Items]
Total capital expenditures									($43,793)
[1]	Segment income from operations includes allocated corporate overhead expenses.
[2]	Other corporate expense primarily represents employee stock-based compensation expenses and those expenses associated with the Company's operation as a public entity such as board compensation, audit expense, fees related to the listing of our stock and expenses incurred to pursue potential acquisition opportunities. The amounts presented for fiscal years 2012 and 2011 include corporate overhead previously allocated to the animal health business. These amounts were not reallocated to the remaining segments.

Overhead_Expenses_Allocated_to

Overhead Expenses Allocated to Segment Income (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Segment Reporting Information [Line Items]
Total corporate overhead expense allocation	$9,679	$9,760	$7,403
Electronic Chemicals
Segment Reporting Information [Line Items]
Total corporate overhead expense allocation	5,218	5,354	4,066
Wood Treating
Segment Reporting Information [Line Items]
Total corporate overhead expense allocation	$4,461	$4,406	$3,337

Reconciliation_of_Total_Segmen

Reconciliation of Total Segment to Consolidated Amounts (Detail) (USD $)	3 Months Ended										12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013		Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012		Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2013		Jul. 31, 2012		Jul. 31, 2011
Segment Reporting Information [Line Items]
Total assets for discontinued operations	$467	[1]				$467	[1]				$467	[1]	$467	[1]
Other current assets	9,120					3,627					9,120		3,627
Other assets	8,413					7,572					8,413		7,572
Total assets	262,015					167,690					262,015		167,690
Other corporate expense											-7,334	[2]	-3,577	[2]	-3,949	[2]
Net sales	81,087		59,929	56,959	65,336	67,607		66,579	66,975	71,539	263,311		272,700		255,596
Operating income	2,525		4,355	3,196	7,104	6,695		6,868	4,883	6,991	17,180		25,437		17,022
Interest expense, net											-1,771		-2,099		-2,335
Other expense, net											-208		-269		-208
Income from continuing operations before income taxes	1,915		3,918	2,725	6,643	6,131		6,316	4,256	6,366	15,201		23,069		14,479
Property, plant and equipment, net	96,688					68,026					96,688		68,026
United States
Segment Reporting Information [Line Items]
Net sales											200,184		229,140		218,961
Property, plant and equipment, Domicile	51,720					52,178					51,720		52,178
International
Segment Reporting Information [Line Items]
Net sales											63,127		43,560		36,635
Property, plant and equipment, Foreign Countries	44,968					15,848					44,968		15,848
Reportable Segments
Segment Reporting Information [Line Items]
Total assets	244,015					156,024					244,015		156,024		160,846
Net sales											262,940		272,485		255,596
Operating income											24,514	[2],[3]	29,014	[2],[3]	20,971	[2],[3]
All Other Segments
Segment Reporting Information [Line Items]
Net sales											$371	[4]	$215	[4]
[1]	Reflects deferred tax assets as of July 31, 2013 and 2012.
[2]	Other corporate expense primarily represents employee stock-based compensation expenses and those expenses associated with the Company's operation as a public entity such as board compensation, audit expense, fees related to the listing of our stock and expenses incurred to pursue potential acquisition opportunities. The amounts presented for fiscal years 2012 and 2011 include corporate overhead previously allocated to the animal health business. These amounts were not reallocated to the remaining segments.
[3]	Segment income from operations includes allocated corporate overhead expenses.
[4]	Primarily reflects fees from the transition services agreement in connection with the sale of the animal health business. The agreement terminated on March 1, 2013. See Note 12.

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Quarterly Financial Data [Line Items]
Net sales	$81,087	$59,929	$56,959	$65,336	$67,607	$66,579	$66,975	$71,539	$263,311	$272,700	$255,596
Gross profit	24,328	16,333	15,721	20,088	20,643	20,606	17,141	18,675	76,470	77,065	68,060
Operating income	2,525	4,355	3,196	7,104	6,695	6,868	4,883	6,991	17,180	25,437	17,022
Income from continuing operations before income taxes	1,915	3,918	2,725	6,643	6,131	6,316	4,256	6,366	15,201	23,069	14,479
Net income	$723	$2,865	$1,618	$4,142	$3,863	$3,965	$2,462	$3,535	$9,348	$13,825	$9,729
Income per share from continuing operations
- basic	$0.07	$0.25	$0.14	$0.36	$0.35	$0.34	$0.22	$0.34	$0.82	$1.26	$0.83
- diluted	$0.07	$0.25	$0.14	$0.36	$0.34	$0.33	$0.22	$0.34	$0.82	$1.24	$0.82
Net income per share
- basic	$0.06	$0.25	$0.14	$0.36	$0.34	$0.35	$0.22	$0.31	$0.81	$1.22	$0.86
- diluted	$0.06	$0.25	$0.14	$0.36	$0.33	$0.34	$0.21	$0.31	$0.81	$1.20	$0.85

Recovered_Sheet3

Schedule II - Valuation And Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Allowance for Doubtful Accounts
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$16,000	$414,000	$260,000
Charged to costs and expenses	208,000		154,000
Additions/ Deductions		-398,000
Balance at end of period	224,000	16,000	414,000
Inventory Valuation and Obsolescence
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	493,000	333,000	418,000
Charged to costs and expenses	107,000	272,000	-34,000
Additions/ Deductions	-420,000	-112,000	-51,000
Balance at end of period	180,000	493,000	333,000
Valuation Allowance of Deferred Tax Assets
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period			627,000
Charged to costs and expenses			($627,000)